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Abstract
The World Health Organization has classified schizophrenia as one of the five
leading causes of disability worldwide. Afflicting almost 1% of the world’s
population, the disease’s greatest impact stems from its reduction in patients’
cognitive faculties. In order to better study these impairments, a pharmacological
model has been developed using the NMDA antagonist, ketamine. This disease
model successfully recreates the cognitive dysfunction of schizophrenia, allowing
researchers to search for associated electrophysiological changes.

In this project I examined the behavioural and neurophysiological effects of
ketamine on non-human primates performing the anti-saccade task. Success in
this task requires a degree of cognitive control over behaviour and previous
studies have described poor performance in both patients with schizophrenia and
healthy controls administered ketamine. Our intracranial recordings are localized
in the prefrontal cortex (PFC), a region associated with many of the cognitive
functions impaired in schizophrenia.

The first study shows that neurons in the PFC exhibit selectivity for the task rule.
This rule selectivity is lost after ketamine administration due to an indiscriminate
increase in the neuronal firing rate. These changes were also associated with an
increased error rate and longer reaction times. The second study shows that
neurons in the PFC are also sensitive to the outcome of the trial, firing more for
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either correct or erroneous responses. Once again, selectivity is lost following
ketamine administration and the neurons show increased, nonspecific activity.
Lastly, we recorded the local field potential of the PFC and found changes in the
oscillatory patterns during the anti-saccade task. Prior to ketamine there was a
significantly stronger beta-band activity after correct trials compared to error
trials, but this selective activity was lost due to an overall decrease in the
outcome selective oscillatory events.

These findings show that ketamine’s effect on the PFC is one of selectivity
reduction. Patients with schizophrenia have been shown to require increased
PFC activity but only reach moderate performance levels in cognitive challenges.
It is possible that their brains suffer the same changes highlighted in this
research. Although the signals are still present in their PFC, they are being lost
amongst the noise.

Keywords
Schizophrenia, ketamine, prefrontal cortex, working memory, local field potential,
single neuron electrophysiology, anti-saccade, macaque, performance monitoring
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Epigraph

“Any man could, if he were so inclined, be the sculptor of his own brain.”
― Santiago Ramón y Cajal, Advice for a Young Investigator (1897)
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Chapter 1

Introduction
1.1 - Schizophrenia
Schizophrenia is a debilitating mental disorder affecting nearly 1% of the world’s
population. A recent report by the World Health Organization ranked it among the
5 leading causes of disability worldwide (World Health Organization, 2008). In
Canada alone this accounts for over 230,000 individuals (Goeree et al., 2005)
and as a result produces a large strain on an already exhausted healthcare
system. It has been estimated the morbidity of the disease accounts for 70% of
the disease burden due to lost work (Goeree et al., 2005). Due to the
symptomatic profile of the disease schizophrenia’s effect on Canada’s economy
extends beyond the patient, negatively impacting the working life of the patients’
family and loved ones as well. Patients with schizophrenia also have a much
greater risk for suicide, estimated to be between 15 and 25 times higher than that
observed in the general population (Allebeck, 1989; Caldwell and Gottesman,
1992). The future of treatments for schizophrenia is not encouraging either, with
many pharmaceutical companies withdrawing from antipsychotic research
because of poor returns (Hyman, 2012).

1.1.1 Etiology
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There is currently no known etiology for the disease but a number of genetic
and environmental factors have been proposed. A gene X environment
hypothesis attempts to combine these findings by suggesting that genetic and
epigenetic factors may pre-dispose an individual for schizophrenia but
environmental factors add a second hit to these vulnerable persons and are the
ultimate trigger for disease progression (Tsuang, 2000). Current studies have
found that environmental risk factors include maternal infection during the second
trimester of pregnancy, an urban upbringing, and even belonging to an immigrant
group (Jablensky, 2000). Genetic susceptibility plays a strong role as well, with
increasing genetic similarities increasing the risk of developing the disease; yet
monozygotic twins only have a 50% concordance rate (Gottesman, 1991). The
disease has a relatively later onset - in the late teens for males and early twenties
for females - which confounds prospective studies but also influences a number
of developmental models of the disease. Since this period in the brain’s
development consists of the final stages of neural pruning (Rakic et al., 1986;
Rakic et al., 1994; Huttenlocher and Dabholkar, 1997; Insel, 2010), a growing
body of evidence suggests that deficits in neural plasticity may contribute to the
negative and cognitive symptoms of schizophrenia (Feinberg, 1982, 1990;
Keshavan et al., 1994). The brain’s ability to dynamically increase the strength of
some pathways while decreasing (or pruning) others has already been well
established to be critical in an organism’s ability to learn and exhibit cognitive
control over their actions (Segal, 2005). Thus, a disruption in the delicate balance

3
of this process could manifest as profound disabilities in a patient’s cognitive
faculties.

1.1.2 Symptoms
While schizophrenia is often associated with delusions and hallucinations
(Stuart and Arboleda-Florez, 2001), these two symptoms are only a small part of
a much larger spectrum of problems experienced by a patient with the disease.
The problems are often broken down into three general categories of symptoms
(Insel, 2010). Positive symptoms are those that produce traits or experiences not
found in the non-schizophrenic population, such as auditory hallucinations and
delusions of grandeur, paranoia, or persecution. Opposite to these are the
negative symptoms, or traits not observed in the patient with schizophrenia that
are present in the general population. Examples of this include anhedonia, social
withdrawal, and emotional flattening. These two symptom categories follow
different patterns of expression. While positive and negative symptoms often
occur suddenly together in an acute event termed the ‘first-episode’, the negative
symptoms only have a slow but constant worsening while positive symptoms
have a fluctuating pattern of onset and offset.

Lastly, patients also experience deficits in their cognitive abilities including
poor executive function, impaired memory, decreased concentration, and deficits
in performance monitoring (Harvey, 1985; Heinrichs and Zakzanis, 1998;
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Greenwood et al., 2005; Sergi et al., 2005). It has now been acknowledged that
the cognitive symptoms constitute the core feature of schizophrenia and are most
responsible for the disability associated with the disease (Elvevag and Goldberg,
2000).

Cognitive symptoms appear slightly later and plateau for the majority of
the patient’s life, only to suddenly worsen after the age of 65 (Figure 1) (Harvey
et al., 1999). Clinicians have found that specific tasks such as the Stroop task
(Stroop, 1935) are very effective at establishing the severity of cognitive deficits
common in patients with schizophrenia (Cohen et al., 1999). The task involves
showing patients names of colors printed in a different color than the one
described, for example the word ‘red’ may appear printed in blue ink. By asking
the patients to either read the word or name the color of the ink, the examiner
can test the patient’s cognitive control over visual input and response.
Schizophrenic patients are lacking in this dimension of cognitive control leading
to increased error rates and can take much longer than control subjects when
asked to state the color of the ink instead of reading the word (Perlstein et al.,
1998; Henik and Salo, 2004). Additionally, patients are very often subject to
increased impulsivity. Poor cognitive control over behavior and a strong
‘stimulus-driven’ behavioural profile have been suggested to be factors
contributing to poor societal integration, substance abuse, and increased
suicidality (Gut-Fayand et al., 2001; Enticott et al., 2008).
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Figure 1.1: Schematic of schizophrenia symptom progression. It is unknown whether there is an
event that occurs before the first episode but almost all cases begin with an acute episode of
psychosis. The positive symptoms fluctuate throughout the course of the disease while the
negative symptoms slowly progress over the entire course. Cognitive symptoms remain
relatively stable after the first deterioration but often become much worse after 65. Data adapted
from (Wiersma et al., 1998; Hafner et al., 1999; Harvey et al., 1999; Mancevski et al., 2007) .
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1.1.3 Search for the Underlying Neuropathology of Schizophrenia
At the gross anatomical level, computerized tomography studies as early
as the 1970s have found that patients with schizophrenia were more likely to
display enlarged lateral ventricles (Johnstone et al., 1976; Weinberger et al.,
1979a). Coinciding with this was a dilation of their interhemispheric and sylvan
fissures (Weinberger et al., 1979b). Metabolic studies of schizophrenic patients’
brains showed a decreased blood flow in the frontal cortex (Ingvar and Franzen,
1974) as well as a decrease in their frontal cortex glucose usage (Buchsbaum et
al., 1982; Wolkin et al., 1985). With the increased availability of MRI, researchers
soon discovered more subtle changes in the decreased brain tissue previously
described. Studies confirmed the ventricular enlargement observed in CT studies
but also noted a decrease in the grey:white matter ratio within the prefrontal
cortex of patients with chronic schizophrenia (Figure 1.2) (Shenton et al., 2001).
Additional MRI studies found correlations between the degree of change in
prefrontal cortex volume and severity of negative and cognitive symptoms (Baare
et al., 1999; Wible et al., 2001). Taking these results further with fMRI research,
studies found that tasks with high cognitive demands like those requiring working
memory, those requiring performance monitoring, and those involving inhibitory
control over motor function showed abnormal activation of the prefrontal cortex
(PFC) that was significantly different from controls (Manoach et al., 1999;
Manoach et al., 2000; Carter et al., 2001; Rubia et al., 2001). Non-diagnosed
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Figure 1.2: Coronal MRI sections of a normal control patient (left) and a patient with chronic
schizophrenia (right). The arrow indicates an area of increased CSF in the sylvan fissure.
Additionally, the increased lateral ventricle space in the patient with schizophrenia is visible.
Reproduced with permission from: Shenton ME, Kikinis R, Jolesz FA, Pollak SD, LeMay M,
Wible CG, Hokama H, Martin J, Metcalf D, Coleman M, McCarley RW (1992) Abnormalities of
the Left Temporal Lobe and Thought Disorder in Schizophrenia — A Quantitative Magnetic
Resonance Imaging Study. The New England Journal of Medicine 327:604-612. Copyright
Massachusetts Medical Society.
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siblings of schizophrenic patients also displayed these same changes in their
PFC activity (Callicott et al., 2003).

Many changes in the brains of patients with schizophrenia have also been
described at the cellular level. While pyramidal cells in the PFC remain largely
unchanged between normal controls and patients with schizophrenia, the density
of small interneurons is decreased in diseased brains (Benes et al., 1991). It was
later discovered that this decrease was associated with parvalbumin (PV+)
expression, an intracellular marker for a subset of interneurons (Hashimoto et al.,
2003). These neurons have a high density of gamma aminobutyl acid (GABA)
releasing terminals and thus are classified as inhibitory interneurons (McBain and
Fisahn, 2001; Markram et al., 2004). Another intracellular marker associated with
schizophrenia is the enzyme glutamate decarboxylase (GAD67), which is
responsible for the synthesis of GABA (Erlander et al., 1991). Post-mortem
studies have very consistently found that GAD67 mRNA is downregulated in the
dorsolateral PFC (dlPFC) of patients with schizophrenia (Akbarian et al., 1995;
Mirnics et al., 2000; Volk et al., 2000). This down regulation of GAD67 was found
to be particular to PV+ interneurons and most notably that those interneurons
with lower than normal PV+ expression were the same neurons that showed an
absence of the expected GAD67 enzyme (Hashimoto et al., 2003). It is apparent
that in the schizophrenic dlPFC the PV+ class of interneurons may be suffering
from a functional impairment due to a decreased ability to synthesis GABA and
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consequently are unable to properly inhibit post-synaptic pyramidal neurons
(Lewis et al., 2012).

Aside from GABA transmission, the excitatory neurotransmitter glutamate
has been implicated in schizophrenia as well (Olney and Farber, 1995).
Glutamatergic receptors have been found to be downregulated in the PFC as well
as the thalamus and hippocampus in schizophrenic patients (Konradi and
Heckers, 2003). As the primary excitatory neurotransmitter system, this downregulation has been regarded as a potential contributor to the ‘hypofrontal’ state
associated with schizophrenia (Paz et al., 2008; Marek et al., 2010). Indeed, a
blockade of the N-methyl D-aspartate (NMDA) type of glutamate receptors on
PV+ interneurons with the antagonist ketamine induced a decrease in the GAD67
and PV expression of these cells (Kinney et al., 2006).

Dopamine was the first neurotransmitter implicated in the pathology of the
disease, due to the therapeutic effects of dopamine receptor antagonists (for
review see Seeman, 1987). While these findings were consistent with the positive
symptoms of schizophrenia, the models of the disease and therapies targeting
the dopaminergic system were less successful at describing the negative and
cognitive dimensions (Angrist et al., 1980; Lipska and Weinberger, 2000; Neill et
al., 2010). A post-mortem study found that dopamine was decreased in the
dlPFC of patients with schizophrenia (Abi-Dargham and Moore, 2003). Possibly
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to compensate for this decreased dopamine, another study found that an
increased dopamine D1 receptor availability in this area was associated with poor
performance during a working memory task in patients with schizophrenia (AbiDargham et al., 2002). Interestingly, the previously mentioned PV+ interneurons
are the only type of interneuron within the PFC to receive dopaminergic synaptic
inputs (Sesack et al., 1998).

Taken together, the functional disabilities and neuroanatomical changes
point to a strong role of the prefrontal cortex in schizophrenia symptomology.

1.2 Prefrontal Cortex
Initially described by Brodmann in the early 20th century, the PFC was
believed to be unique to primates (Brodmann, 1905; Brodmann, 1909). Years
later it was discovered that analogous regions existed in non-primate mammals
such as rabbits, sheep, cats, and rats as defined by the projections from the
medial dorsal (MD) nuclei of the thalamus terminating in these areas of the
frontal cortex (Rose and Woolsey, 1948; Akert, 1964; Divac et al., 1978a).
Localized subdivisions of the PFC were also identified based on their anatomical
connectivity and cytoarchitecture (Brodmann, 1905; Walker, 1940; Petrides and
Pandya, 1999; Petrides, 2005). Newer techniques using functional magnetic
resonance imagining (fMRI) have gone further and identified functional
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connectivity in the human and non-human primate PFC (Hampshire and Owen,
2006; Hampshire et al., 2012; Hutchison and Everling, 2013).

When classifying these regions based on their cytoarchitecture,
researchers often look at the distribution of cell types in the various layers of
cortex. The granulated cortex is the histological attribute that defines the
difference between the primate dlPFC and other PFC subregions (Brodmann,
1909). This name stems from the granulated appearance of neurons within layer
IV of the lateral PFC, also named the internal granulated layer (Preuss, 1995).
Particularly in the dlPFC (Brodmann areas 9/46), layer IV in these regions is
much denser and better developed when compared to other bordering regions
(Figure 1.3) (Petrides and Pandya, 1999). The density and increased
development of layer IV in these regions is in part due to the MD thalamic
projections terminating in this area (Tobias, 1975) as well as the highest
concentration of Pv+ neurons (Hashimoto et al., 2003). Structural connectivity
experiments involving the injection of tracer dyes showed that area 9/46, or the
dorsolateral and ventrolateral prefrontal cortex had extensive inputs from
multimodal areas such as the superior temporal sulcus, rostral superior temporal
gyrus, and the anterior & posterior cingulate cortex (Petrides and Pandya, 1999).
Their outputs projected onto both temporal multimodal areas as well as
paralimbic areas like the cingulate and retrosplenial cortex (Petrides and Pandya,
1999). Initial studies on the cytoarchitecture in the PFC examined and defined
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Figure 1.3: Sagittal illustrations of the frontal lobe of humans, macaque monkeys, and rats.
Homologous areas are mapped between species by their indicated colours. The granulated
prefrontal cortex has no corollary area in the rodent brain but agranular regions are still present.
Reprinted with permission from: Wise SP. (2008) Forward frontal fields: phylogeny and
fundamental function. Trends in Neuroscience. 31(12):599–608.
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these areas separately in the human and non-human primate PFC (Brodmann,
1905; Brodmann, 1909; Walker, 1940). More recent research efforts have now
collated this data with additional experiments, resulting in area definitions that are
applicable across both species (Petrides and Pandya, 1999).

Differences still remain between the PFC of the two most common animal
models used for schizophrenia: rodents and non-human primates (Brown and
Bowman, 2002). Whereas projections from the MD thalamus terminate in the
medial, orbital, and dorsolateral surfaces of the primate PFC, the rodent PFC
only contains medial and orbital regions (Ongur and Price, 2000). This difference
in PFC subregions is critically important when studying the cognitive functions
impaired in schizophrenia, as higher order brain functions like working memory
(Goldman-Rakic, 1987; Kimberg and Farah, 1993), attention control (MacDonald
et al., 2000), and decision making (Heekeren et al., 2008a) have all been
attributed to the dorsolateral aspect of the primate PFC (Miller and Cohen, 2001).
The rodent may have developed analogous areas or methods of performing
these cognitive tasks, but the two homologous regions (medial and orbital) of
PFC do not substitute for the primate dlPFC (Kolb, 1990). Some aspects of
cognitive deficits in schizophrenia have been associated with the anterior
cingulate cortex (ACC), a medial region of the PFC (Devinsky et al., 1995; Dolan
et al., 1995; Carter et al., 2001). Similarities exist between the ACC and the
medial PFC of rodents, meaning experiments that investigate cognitive
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dysfunction associated with this area have valid homologues in rodent models of
the disease (Preuss, 1995).

The described interconnectedness of the PFC allows it to use highly
processed sensory information to generate a top-down, executive control over
behaviour (Miller and Cohen, 2001). Two components of this executive function
are particularly impaired in schizophrenia: working memory, which maintains,
integrates, and manipulates sensory information over short periods of time
(Goldman-Rakic, 1994); and performance monitoring, which gives feedback on
the outcome of an action in order to better guide actions in the future (Carter et
al., 2001).

1.2.1 Working Memory
Neural computational models of cognitive control often require a set of
neurons to act as a temporary storage space, keeping immediately relevant
information online for the integration of past and present stimuli, previous
outcome experiences, and internally generated goals (Dehaene and Changeux,
1991; Durstewitz et al., 2000). This is achieved through the use of working
memory. Often describe as the scratchpad of the brain, working memory
temporarily retains information to guide future behaviours (Baddeley, 1986).
Appreciating working memory is an important aspect to understanding the overall
function of the PFC as its effects on the brain are extensive (Goldman-Rakic,
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1987). Studies in both humans (Goldman-Rakic, 1987; Fuster, 1997; Knight and
Stuss, 2002) and non-human primates (Funahashi and Kubota, 1994; Petrides,
1994; Funahashi and Takeda, 2002) have verified the importance of the dlPFC in
working memory function.

Working memory function can be demonstrated in a number of modalities.
Tasks like the oculomotor delayed response (ODR) have shown that the dlPFC
has sustained activity during the retention interval, an epoch in the working
memory task that engages spatial working memory (Curtis and D'Esposito,
2003). The ODR task requires a subject to fixate on a central fixation point, after
which a suddenly appearing visual stimulus will be briefly displayed in one of 8
cardinal locations surrounding the fixation point. After the stimulus has
disappeared from the subject’s visual field, they must wait until they receive a cue
instructing them to look towards the blank screen location where the visual
stimulus previously appeared. While they wait for this cue, their spatial working
memory is maintaining the location of where in the visual field the stimulus
appeared, so that they may generate a saccade to the remembered location
when instructed. The sustained activity in the PFC during this retention interval
couples the initial visual stimulus with the later behavioural response. By training
non-human primates on the task, experimenters were able to obtain single
neuron recordings in the dlPFC to show increased activity in the retention interval
(Funahashi et al., 1989; Sawaguchi and Goldman-Rakic, 1994). Single neuron
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recordings in the primate also showed that neurons in the dlPFC were selectively
tuned to specific locations in the visual field (Funahashi et al., 1989, 1990).
These data provided a neurophysiological representation of spatial working
memory in the primate dlPFC.

By incorporating electroencephalography (EEG) methods, researchers
also identified that certain frequencies of neuronal oscillations are sensitive to the
retention interval epoch of the trial during which verbal or spatial working memory
is required. These frequencies may help synchronize the PFC with other regions
of the brain also required for the task (Sarnthein et al., 1998). Higher frequencies
were negatively correlated with the difficulty as well, which led researchers to
conclude that there is a quantifiable working memory load that exists within the
PFC and it can be measured through EEG (Gevins et al., 1997).

Aside from the spatial location of a visual stimulus, working memory can
also maintain features of an object, as demonstrated by the delayed match-tosample task (Hasegawa et al., 1998). In this task, the subject is briefly shown an
object, after which they must remember the identity of the object over a delay
period while continuing to hold a hand lever. During this delay period of this task
the subject’s dlPFC was shown to exhibit sustained neuronal activity analogous
to the activity observed in the ODR task. Following the brief delay period, the
subject is shown another object and they are required to release the lever if the
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object is the same as the cue object previously shown. The sustained activity
recorded in the dlPFC during the delay period was found to be dependent on
what object was being stored, a feature of working memory similar to the
selectivity observed in spatial working memory (Miller et al., 1996; Johnston and
Everling, 2006b).

Not limited to only storing simple properties of visual stimuli, the working
memory system is capable of operating at a higher order level through the
storage of abstract rules (Wallis et al., 2001). This rule-based working memory is
then employed by the subject to guide an imminent behavioural response to a
stimulus (Bunge, 2004). In these tasks it is not the stimuli that is being stored,
rather an internally developed concept associated with a visual cue that is being
maintained in working memory (Miller and Cohen, 2001). Neurons within the
dlPFC have been recorded that display a selectively increased activity for specific
rules during the delay period (Wallis et al., 2001; Everling and DeSouza, 2005;
Johnston and Everling, 2006b; Johnston et al., 2009) and these neurons project
directly to the superior colliculus, an area responsible for the generation of the
oculomotor response (Everling et al., 1999; Johnston and Everling, 2006a).

Proper dlPFC function is required to use these learned rules to guide
behaviour, as is evident by the increased error rate in the face of an incongruent
or stimuli-response challenge, such as the previously described Stroop Task
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(Perret, 1974; Alexander et al., 2007) or the anti-saccade task (Hallett, 1978;
Guitton et al., 1985) following PFC damage. Although other brain regions are
also involved in this working memory activity, the PFC is the only region in which
impairment causes severe deficits in task performance (Kane and Engle, 2002).
Functional MRI scans showed the strongest BOLD signals in the lateral PFC
during working memory tasks (Owen, 1997). Theoretical models first predicted
that because of its ubiquitous nature, working memory impairment might have a
widespread impact on general cognitive function (Kimberg and Farah, 1993).
This diverse cognitive disability stemming from impaired working memory was
later confirmed to occur in humans (Silver et al., 2003; Alexander et al., 2007;
Koerts et al., 2009). Similar cognitive disabilities may also arise due to deficits in
error monitoring, another executive function associated with the PFC.

1.2.2 Error monitoring and performance feedback
The purpose of performance monitoring is to gather information regarding
the outcome of a trial in the context of the behavior used to reach this outcome.
Both correct and error outcomes have been shown to elicit specific neuronal
responses, where neurons may be selective for only one of the two. This
outcome specific activity has been localized to the ACC, a region bordering the
PFC (Carter and van Veen, 2007). Different regions of the ACC have been
shown to exhibit different activation patterns for correct or erroneous outcomes
(Holroyd et al., 2004; Margulies et al., 2007). The ACC is connected via
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dopamine projections to the ventral tegmental area, which allows correct
conditions to produce an intrinsic sensation of reward and network reinforcement
(Divac et al., 1978b; Watanabe, 1990; Leon and Shadlen, 1999). Reciprocal
connections to the lateral PFC (Bates and Goldman-Rakic, 1993; Petrides and
Pandya, 1999) combine this performance information with associated behaviors
and goals stored in working memory (Watanabe, 1992; Ridderinkhof et al., 2004).
Together, this network acts to make sense out of action-outcome sets.

The first demonstration of the outcome sensitivity of neurons in the ACC
was recorded using intracranial electrodes in non-human primate ACC. The
experiment employed a task that required the animal to exert cognitive control
over their response to a cue, delaying the trained behavioural reaction in order to
gain a reward (Niki and Watanabe, 1979). In these experiments, it was
determined that neurons showed sensitivity not only to either a correct or error
outcome, but that the stimulus tied to the outcome could also influence the ACC
activity. An additional study confirmed these results and found that if the animal
performed a correct trial but no reward was given, it was the error neurons that
increased their activity in the performance-monitoring epoch (Amiez et al., 2005).
Neurons within the rodent ACC were also found to assemble into coherent
states, where a network of neurons would organize in discernable patterns
dependent on the cognitive demands of the task and falter during tasks with error
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responses (Lapish et al., 2008).

This sensitivity of the ACC to erroneous

responses had previously been demonstrated in humans through EEG studies.

One of the soundest and most reproducible EEG findings in the human
PFC is the error related negativity (ERN) response. First described in simple
reaction time tasks (Falkenstein et al., 1991), the ERN is a brief negative
deflection of the event-related potential as recorded by EEG over the ACC
(Yeung et al., 2004). The ERN regularly occurs 100ms after the subject has
made an erroneous response to a stimulus and has been described in humans
and non-human primates alike (Falkenstein et al., 2000; Godlove et al., 2011;
Phillips and Everling, 2014). The robust nature of the ERN is due in part to its
occurrence in the ACC independent of both the modality of stimuli presentation
and behavioural response required (Holroyd et al., 1998). The ERN can be
triggered in two types of errors. The first type occurs when the subject makes a
behavioural response that the ACC recognizes to be erroneous and attempt to
remedy by quickly switching to the correct response. This type of intrinsic error
correction can often go unnoticed by the subject and the behavioural correction
occurs too fast to be consciously registered (Murphy et al., 2012). The second
ERN trigger occurs when the subject performs a task correctly and is expecting a
reward but receives none (Holroyd et al., 2003; Yasuda et al., 2004). It has been
hypothesized that this second type of ERN helps the PFC to continually adjust to
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which behaviours will not be rewarded and suppresses those unrewarded events
appropriately (Walsh and Anderson, 2012).

The localization of performance monitoring to the PFC has implications in
humans with abnormal PFC function, such as patients with schizophrenia or
those that have sustained PFC damage. Without the ability to properly detect
correct responses from errors, the entire network of behavioural modification and
optimization begins to suffer. Consequently, in both of these situations
experiments have shown that patients have trouble adapting their behavior in the
face of incorrect responses and error outcomes. Error monitoring deficits are
particularly evident in patients with schizophrenia, as EEG studies have found a
decrease in the amplitude of the ERN (Kopp and Rist, 1999), as well as a
decreased BOLD signal during the performance-monitoring epoch of a trial
(Carter et al., 2001). Commonly patients with schizophrenia report a feeling that
their thoughts and behaviours are being externally controlled (O'Grady, 1990).
This unique symptom has been attributed to a disturbance in their ability to
recognize and monitor internally generated actions (Frith, 1987; Frith and Done,
1989). The decreased awareness of behavioral outcomes leads to a subsequent
decrease in the general cognitive awareness of the patient’s sense of self.
Interestingly, many of these symptoms associated with schizophrenia have been
elicited with compounds that antagonize the NMDA glutamate receptor.
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1.3 Glutamate
Glutamate is the primary excitatory neurotransmitter of the brain,
ubiquitous across the central nervous system and necessary for the transfer of
action potentials across the synaptic cleft (Fain, 1999). It acts primarily on three
classes of post-synaptic ionotropic receptors. The α-amino-3-hyrdoxy-5-methyl-4isoxazoleproprionic acid (AMPA) receptors are responsible for the fast response
to presynaptic glutamate release and initiate the excitatory post-synaptic potential
(EPSP) at the post-synaptic density (Meldrum, 2000). The kainite receptor family
is poorly understood but it appears to have a role in the regulation of the AMPA
and NMDA receptor responses in the synapse (Lerma and Marques, 2013).
Lastly is the NMDA receptor, which has been the most extensively studied and
has been implicated in a number of neurological disease models (Dingledine et
al., 1999).

1.3.1 NMDA Receptor
The NMDA receptor was named after a selective agonist for this subtype
of glutamate receptor. It is a voltage gated Ca2+ channel that has a Mg2+ ion
resting inside the channel pore during its inactive state, This Mg2+ ion acts as a
plug to prevent the inward flow of Ca2+. Upon depolarization the Mg2+ ion is
released and the receptor goes through a conformational change to open the ion
channel. The open pore allows an influx of Ca2+ which helps to release additional
intracellular stores of Ca2+ and subsequently cause depolarization. This
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ultimately leads to the generation of an action potential (Figure 1.4). NMDA
activation is also required for the changes in the post-synaptic receptor profile
that produce long-term potentiation and neuronal plasticity (Malenka and Nicoll,
1999). The most common class of antagonist for the NMDA receptor acts by
binding inside the channel pore near the Mg2+ binding site (Kroemer et al.,
1998). This secluded location for the antagonist binding site requires the
activation of the receptor before the compound can bind and exert its effect (Anis
et al., 1983). The pharmacodynamic profile induced by this antagonist binding
pattern shows higher binding rates with higher values of agonist and is called
uncompetitive antagonism. Uncompetitive antagonists for the NMDA receptor
such as ketamine, phencyclidine (PCP), and dizocilpine (MK-801), have all been
shown to have very potent effects on the activity of neurons at the cellular level
and were initially used in high doses to produce an anesthetic effect. However, at
subanesthetic doses, these drugs can produce startling behavioural changes
(Lipton, 1993, 2004). Of all of the NMDA uncompetitive antagonists, ketamine
has been studied most extensively because of the similarities between its
behavioural effect profile and the behavioural phenotypes observed in patients
with schizophrenia.
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Figure 1.4: The NMDA receptor and the ketamine binding site. This ionotropic receptor requires
two steps for activation. First, an agonist must bind to an extracellular site to induce a
conformational change and second, the membrane surrounding the receptor must become
2+
2+
depolarized to free the Mg block in the channel. This allows Ca to enter the cell. Reprinted
with permission from: Frohlich J and Van Horn JD (2014).Reviewing the ketamine model for
schizophrenia. Journal of Psychopharmacology 28(4) 287-402.

25
1.3.2 Ketamine
First created in 1962 as a less neurotoxic alternative to PCP (Rowland,
2005), ketamine was intended to be used as a dissociative anesthetic that would
produce fewer side effects such as hallucinations and delirium that were common
with PCP (Corssen and Domino, 1966). Since its initial discovery, it has been
found to exert analgesic and amnesic effects as well, both of which are
complementary to its intended purpose as a surgical anesthetic. More recent
studies have suggested it may even have clinical use as a treatment for
intractable major depressive disorder (Berman et al., 2000) and post-traumatic
stress disorder (Feder et al., 2014). Hallucinations are a known side-effect of the
drug, however they are rare in children under the age of 16 years old (Reich and
Silvay, 1989), which is similar to the rarity of schizophrenia presenting with a first
episode of psychosis before late adolescence (Hafner et al., 1993). After the
administration of ketamine in vitro, a washout period is sometimes observed that
can produce spontaneous action potentials in the absence of EPSP input,
possibly due to a neurophysiological response to the drug that increases the
NMDA receptor current for sodium, leaving the neurons more easily excitable
(Benoit et al., 1986).

Despite ketamine’s antagonism of an excitatory receptor, it has been well
documented that it - and other NMDA antagonists - have a net positive effect on
the general excitatory activity of the brain. It has been suggested that this is due
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to an increase in compensatory glutamate release (Rowland, 2005; Kim et al.,
2011; Stone et al., 2012). Due to the increased glutamate release following
NMDA receptor antagonism, this family of drugs is prone to inducing
excitotoxicity in the brain (Horvath et al., 1997; Wozniak et al., 1998; Farber and
Olney, 2003). Human studies have shown that the behavioural changes
associated with this drug can be attenuated by blocking the ketamine-induced
glutamate release, particularly the increased activity in the ACC (Deakin et al.,
2008). Additionally, there is a strong correlation between the amount of glutamate
released in response to ketamine and the severity of the ketamine-induced
psychotic symptoms (Stone et al., 2012).

The NMDA receptor and the functional effects of its antagonism are of
particular importance when discussing schizophrenia. Post-mortem studies of the
brains of schizophrenic patients have demonstrated decreased levels of proteins
required for functional NMDA receptors (Karlsgodt et al., 2011). Polymorphisms
of the NMDA receptor subunits have also been found in patients with
schizophrenia (Li and He, 2007). The link between NMDA receptor function and
schizophrenia is further strengthened by studies that found specific NMDA
hypofunction via both post mortem mRNA analysis and positron emission
tomography (PET) scans in the brains of schizophrenics (Law and Deakin, 2001;
Pilowsky et al., 2006). The PET study also found that the level of behavioural
abnormalities induced by blocking the NMDA receptor with ketamine was
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correlated with the amount of dopamine released in the lateral PFC and the ACC.
This hyper-responsive dopaminergic state in the frontal cortex is often observed
in rodent models of schizophrenia employing NMDA receptor antagonists such
as PCP. These animals show an increased sensitivity to the dopamine-releasing
properties of amphetamine in their frontal cortex (Javitt et al., 2004). Similarly,
human schizophrenia patients also have a heightened response to amphetamine
at both the cellular and functional level (Laruelle et al., 1996; Breier et al., 1997).

1.4 Pharmacological Models of Schizophrenia
These concepts highlight the two strongest theories behind the
neurophysiology of schizophrenia; the dopamine hypothesis and the more recent
glutamate hypothesis. Taking cues from the observation that dopamine receptor
antagonists were successful at treating the positive symptoms of schizophrenia
(Seeman and Lee, 1975), the dopamine hypothesis posits that the behavioural
abnormalities observed in the disease stem from an excessive amount of
dopamine signaling in the striatum (Seeman, 1987) and decreased dopamine
signaling in the prefrontal cortex (Abi-Dargham and Moore, 2003). Unfortunately,
these anti-dopaminergic drugs were unsuccessful at ameliorating the most
debilitating negative and cognitive symptoms of the disease (Lieberman and
Stroup, 2011).
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The more recent hypothesis involving glutamate dysregulation stemmed
from the description of a schizophrenia-like phenotype in human patients
administered PCP (Erard et al., 1980). This concept did not gain traction until the
pharmacological properties of PCP were better understood (Javitt and Zukin,
1991) and the shortcomings of the dopamine theory became apparent. Similar to
its synthesis history, ketamine became preferred over PCP as a model of
schizophrenia because of its decreased neurotoxicity. The acute administration
of either of these NMDA antagonists induced a behavioural profile very similar to
schizophrenia in normal patients and triggered a psychotic episode in patients
already diagnosed with schizophrenia (Krystal et al., 1994). These behaviours
include very specific types of memory disturbances and thought disorders that
are fairly unique to schizophrenia (Adler et al., 1999a). Dopamine dysregulation
is likely still involved in the etiology of schizophrenia but it is probably occurring
as a downstream repercussion of changes in the NMDA receptor activity
(Roberts et al., 2010). For example, chronic users of NMDA antagonists have
shown alterations in their dopaminergic signaling similar to patients with
schizophrenia (Jentsch and Roth, 1999).

1.4.1 Parallels between Schizophrenia and the NMDA Antagonism Model
While NMDA antagonists can induce a net increase in neuronal activity
(Homayoun and Moghaddam, 2007), chronic use of either PCP (Cochran et al.,
2003) or ketamine (Deakin et al., 2008) have been shown to cause a regional
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hypoactivity in the prefrontal cortex. Once again, we see a parallel in the human
schizophrenia population with patients often displaying a hypofrontal pattern of
activation (Liemburg et al., 2012). Additionally, chronic ketamine use decreases
prefrontal grey matter in a similar fashion to the decreased grey matter found in
MRI scans of schizophrenia patients (Liao et al., 2011).

Similar to the ERN, the mismatch negativity (MMN) is a phenomenon
observed in EEG studies on patients with schizophrenia. The MMN response is a
brief negative potential elicited after a different stimulus appears to a subject’s
sensory field after they have been presented with a repeating and unchanging
stimuli. For example, a patient may be continually presented with series of blue
circles but the 10th circle in the series is coloured red instead. This red circle is an
oddball stimulus and will elicit a MMN. This effect holds true with auditory stimuli
as well. In patients with schizophrenia, the MMN event is blunted both in
amplitude and duration. The ketamine model of schizophrenia causes an
identical change in the MMN response in normal subjects treated with ketamine
(Oranje et al., 2000; Umbricht et al., 2000; Kreitschmann-Andermahr et al., 2001;
Heekeren et al., 2008b; Schmidt et al., 2012). Non-human primates treated with
ketamine (Gil-da-Costa et al., 2013) and other NMDA antagonists also display a
similar change in their MMN response (Javitt et al., 1994; Javitt et al., 1996).
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The links between the disease and disease model extend down to the
cellular level as well. Interneurons that express the protein Pv express the protein
at lower level in patients with schizophrenia (Hashimoto et al., 2003). These Pv+
interneurons have a very strong glutamatergic inputs synapsing onto them in the
PFC (Melchitzky and Lewis, 2003), the region most associated with
schizophrenia. This is especially interesting for the ketamine model of
schizophrenia, as it has been shown that Pv+ interneurons are strongly affected
by PCP, ketamine, and other NMDA antagonists in their Pv expression and ability
to inhibit PFC neurons (Cochran et al., 2003; Behrens et al., 2007). With NMDA
receptors driving the excitation of GABA-releasing inhibitory interneurons, proper
NMDA receptor function is critical for the inhibition and synchronization of
pyramidal cells in the PFC (Behrens et al., 2007; Homayoun and Moghaddam,
2007). This decreased inhibitory control has been linked to the manifestation of
behavioural changes caused by ketamine through the use of GABA agonists.
The administration of a GABA agonist shortly after the ketamine administration
resulted in an amelioration of the normal behavioural changes expected with
ketamine (Castner et al., 2010). In summary, it is the NMDA receptor
hypofunction that is causing a disinhibtion of the PFC network via decreased
excitatory input to the Pv+ GABAergic interneurons. These changes are
cumulative as well, with chronic administration of NMDA receptor antagonists
permanently altering the post-synaptic environment of these cells (Cochran et al.,
2003; Amitai et al., 2012).
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1.5 Brain Oscillations in Schizophrenia
Interneurons are also responsible for the synchronization of neuronal firing
in the cortex (Lytton and Sejnowski, 1991; Lewis et al., 2005) and thus poorly
functioning interneurons will alter the generation of functionally relevant
oscillatory activity, a necessity for interregional communication in the brain
(Schnitzler and Gross, 2005). Schizophrenia has been proposed to be a disorder
of connectivity (Friston, 1998) with early studies showed fewer functional
interactions between different regions of the brain (Volkow et al., 1988). More
advanced techniques confirmed these findings of global reductions in the
functional connectivity of the schizophrenic brain (Calhoun et al., 2009).
Anatomically, the connections have been shown to be smaller via decreased
axonal and cortical thickness (Bassett et al., 2008; Wang et al., 2011; Zalesky et
al., 2011), while an fMRI analysis of patients with schizophrenia has also shown
that at resting state the brain exhibited fewer hubs of connectivity and a
decreased efficacy of those remaining connections (Lynall et al., 2010).

Researchers have delineated different ranges of oscillatory frequencies
that facilitate these types of long distance communications and neural synchrony.
The most thoroughly investigated range in schizophrenia research is the gamma
band, which is most often defined as frequencies between 30-90 Hz (Lee et al.,
2003). A number of cognitive functions have been associated with gamma band
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oscillations – short-term memory (Tallon-Baudry et al., 1998), working memory
(Haenschel et al., 2009), attention (Tiitinen et al., 1993) and social cognition
(Williams et al., 2009). Patients with schizophrenia demonstrate an increase in
the amplitude of gamma band activity in their PFC during steady-state responses
to stimuli (Plourde et al., 1997), an effect also observed in ketamine-challenged
healthy human subjects (Hong et al., 2010) and animals (Pinault, 2008). The
increase in gamma band activity did not confer improved performance though, as
patients challenged with a working memory task exhibited an increase in the
gamma band activity but an overall decrease in performance (Basar-Eroglu et al.,
2007). Some studies show an increase in the functional connectivity of brain
regions at rest after the administration of ketamine but these increases in
connectivity do not correspond with improved outcomes (Driesen et al., 2013).
Tests with repeated transcranial magnet stimulation (rTMS) have found that the
application of an rTMS field decreased the abnormally high gamma band activity
in patients with schizophrenia during a working memory task (Barr et al., 2011)
and this decrease corresponded with an improved cognitive performance (Farzan
et al., 2012). Further, other studies have found correlations between gamma
band activity and the positive symptoms expressed by schizophrenic patients
(Baldeweg et al., 1998; Kehrer et al., 2008; Spencer, 2008). The remaining
ranges have shown some degree of abnormal function in schizophrenia as well
but their contributions to the schizophrenia phenotype has yet to be fully
discovered (Roopun et al., 2008; Uhlhaas and Singer, 2011, 2012, 2013).

33
1.6 Eye movement deficits in schizophrenia
Previous studies have established that patients with schizophrenia display
abnormalities in a number of dimensions when eye movements are examined.
Two types of canonical movements can be demonstrated in this patient group; a
disturbance in the voluntary control of saccades and dysfunctions when
attempting to perform smooth pursuit movements (Diefendorf and Dodge, 1908;
Kojima et al., 1990). Smooth pursuit movements were reported to be deficient in
patients with schizophrenia by Holzman et al. who demonstrated that eyetracking patterns in this population were disturbed when attempting to follow the
rhythmic movements of a pendulum (Holzman et al., 1974). Further, this study
and others also showed that non-schizophrenic first-degree relatives of these
patients also showed similar but less pronounced deficits, supporting the genetic
component of schizophrenia’s etiology (Hutton and Kennard, 1998; Adler et al.,
1999b).

In contrast to smooth pursuit eye movements, a saccade is the rapid,
reorientation of the fovea onto a new visual location (Munoz and Everling, 2004).
While smooth pursuit eye movements attempt to keep an object on the fovea,
saccades exist to bring a new item or visual field area onto the fovea. Saccadic
eye movements can be prepotent, such as looking towards a suddenly appearing
visual stimulus, or they may be influenced by internal goals such as looking
towards a memorized location (Mort et al., 2003). Cognitive control is required for
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both of these saccade types and this control has been known to be deficient in
schizophrenia (Fukushima et al., 1988; Broerse et al., 2001). A lack of control
over the prepotent saccades would negatively impact an organism’s ability to
focus on salient stimuli and block out irrelevant but novel visual stimuli that act as
distractors (Braff, 1993). In the second type, an animal’s cognitive system is
responsible for integrating their internal cues and memories in order to generate
a target location for the saccade (Broerse et al., 2001; Munoz and Everling,
2004). Both types of saccade can easily be described in the successful operation
of a car. Novel but irrelevant stimuli are constantly presented to a driver’s visual
field while traveling along the road. If the driver were unable to filter these out,
their gaze and attention would not be focused on the road ahead. This unfocused
gaze would eventually cause an undesirable outcome, thus illustrating the
importance of an inhibitory control over prepotent saccades. Alternatively, if the
driver wishes to turn they must look towards the direction they want to travel in
and scan for hazards. This requires the integration of internal goals and previous
memories about visual areas of importance. By purposefully generating a
saccade towards these internally selected saccade locations, the driver is
illustrating the importance of cognitively guided saccades. Both types of cognitive
control over saccades can easily be tested in the laboratory setting with the antisaccade task (Hallett, 1978; Everling and Fischer, 1998; Munoz and Everling,
2004).
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1.7 Anti-saccade task
Originally developed in 1978 by PE Hallet (Hallett, 1978), the anti-saccade
task can probe multiple components of cognition known to be deficient in
schizophrenia. The subject of the experiment is trained to recognize that a visual
rule cue in the form of a red or green coloured circle will indicate whether they are
to make a saccade towards a suddenly appearing novel stimulus (pro-saccade)
or to a location that is diametrically opposite to this novel stimulus (anti-saccade).
Each trial consists of displaying the rule cue to the subject then showing a novel
stimulus either to the left or right of this cue. A successful pro-saccade trial simply
requires the subject to make a saccade towards the novel stimulus. In contrast to
this, if the rule cue indicates an anti-saccade trial the successful completion of
the trial would have the subject looking away from the novel stimulus after its
appearance (Figure 1.5). To complete the anti-saccade trial correctly requires a
number of cognition-controlled steps. First, the subject must suppress the prepotent or stimulus-driven response of automatically looking towards the novel
stimulus. Next, they must generate the voluntary anti-saccade location in their
visual space. This location has no visual indicators so it must be calculated in
relation to the angle and distance of the novel stimulus from the central fixation
point. Lastly, the subject must execute this saccade to the internally generated
saccade target location.
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Figure 1.5: The anti-saccade task. The task can be administered in both rule visible (top row)
and rule memorized (bottom row) conditions. In pro-saccade trials, the subject learns that a
coloured cue represents the pro-saccade rule and indicates that they should saccade towards
the novel stimulus appearing shortly after. The anti-saccade rule is indicated by a different
colour and a successful trial involves looking diametrically opposite of the novel visual stimulus.
Rule memorized versions introduce a delay period during which the subject must maintain the
pro- or anti-saccade rule in their working memory in order to correctly respond to the stimulus
when it appears.
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1.8 Objectives
1.8.1 Examine the effect of ketamine on anti-saccade performance and rulebased working memory in the PFC
A previous study has shown that the ketamine model of schizophrenia is
capable of inducing a behavioural phenotype reminiscent of patients with
schizophrenia when challenged with the anti-saccade task (Condy et al., 2005).
Meanwhile, our laboratory has previously described neurons within the PFC that
are sensitive to the rule for the current trial in the anti-saccade task (Everling and
DeSouza, 2005; Johnston et al., 2009). Since schizophrenia is most commonly
associated with changes in the PFC (Barch et al., 2001) I will look for changes to
these rule-specific neurons in the PFC and analyze the role their activity plays in
the behavioural deficits associated with the ketamine model of schizophrenia.
The goal of this objective is to identify how changes in the PFC activity during
working memory manifest as changes in the subject’s behavioural performance
on the anti-saccade task.

1.8.2 Test for ketamine-induced changes to error monitoring feedback
behaviours and their neuronal representations
Disconnection between brain regions has been hypothesized to have a
strong impact on the cognitive symptoms of schizophrenia. One of the regions
that shares a strong reciprocal connection with the PFC is the anterior cingulate
cortex (ACC), a brain region associated with performance monitoring (Gehring
and Knight, 2000). Studies in human patients with schizophrenia have noted their
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decreased ability to recognize errors in behaviour when they occur (Carter et al.,
2001). Poor performance monitoring activity in the ACC may ultimately be
represented in the schizophrenia-associated PFC where it is integrated with other
signals to produce a behavioural response. Therefore, I will look for these
changes to performance monitoring in the anti-saccade task following the
administration of a subanesthetic dose of ketamine. This data will be combined
with single unit recordings in the PFC before and after ketamine administration to
determine if the ketamine model of schizophrenia produces changes that
coincide with those observed in patients with schizophrenia.

1.8.3 Examine PFC neuronal oscillatory activity for changes caused by ketamine
and their behavioural correlates
Oscillatory neuronal activity has been described as the physiological
phenomenon capable of synchronizing distant regions of the brain and facilitating
interregional communication at a scale greater than single unit activity (Buzsaki
and Draguhn, 2004). Specific frequency ranges of this oscillatory activity have
been shown to be abnormal in the schizophrenic patient (Uhlhaas and Singer,
2010), but the EEG methodology used to record it is limited in its spatial
resolution. Since the PFC is a hub for multiple sources of information, I will
therefore look at a more accurate representation of oscillatory activity within the
PFC by analyzing local oscillatory activity within the PFC both before and after
the administration of ketamine to non-human primates while they perform the
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anti-saccade task. By using intracranial recordings I will be able to identify
changes in this oscillatory activity at a very precise level. Results from this study
will help to relate neuronal oscillatory abnormalities observed externally in the
schizophrenia patient with changes in local field potentials induced by an NMDA
receptor antagonist.

1.9 Summary
It is clear that schizophrenia is a complex mental disorder with a number
of underlying neuronal dysfunctions that all contribute to the final observed
behavioural symptoms. Glutamate, and its signaling through the NMDA receptor,
plays a central role in the disease pathology. Previous studies have shown that
the NMDA receptor antagonist ketamine produces an animal model with a
striking number of resemblances to schizophrenia at both a behavioural and
neurological level. I intend to improve our understanding of how schizophrenia
manifests itself in the dlPFC, a region unique to primates. My project will couple
electrophysiological activity recordings with behavioural performance analysis
during a task that requires cognitive control over saccade responses. I will use
these techniques to investigate how ketamine affects both dimensions
simultaneously and the interaction between neuronal and behavioural changes.
By improving our understanding of the ketamine model of schizophrenia I hope to
ultimately provide us with a better understanding of the disease itself so that
better therapies may be pursued.
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Chapter 2

NMDA antagonist ketamine reduces taskselectivity in macaque dorsolateral prefrontal
neurons and impairs performance of randomly
interleaved pro- and anti-saccades
A version of Chapter 2 is published as K Skoblenick and S Everling, (2012)
NMDA antagonist ketamine reduces task-selectivity in macaque dorsolateral
prefrontal neurons and impairs performance of randomly interleaved pro- and
anti-saccades. The Journal of Neuroscience.

2.1 Introduction
The use of N-methyl-D-aspartate (NMDA) receptor antagonists to induce a
preclinical animal model of schizophrenia has been gaining traction over recent
years. Acute doses of ketamine, a non-competitive NMDA antagonist, have been
shown to induce short-lived behavioural profiles that include the positive,
negative, and cognitive symptoms of schizophrenia in humans (Krystal et al.,
1994; Lahti et al., 1995; Adler et al., 1999; Newcomer et al., 1999; Taffe et al.,
2002). Further, a subanaesthetic dose of ketamine can often trigger a psychotic
episode in patients already suffering from the disease (Malhotra et al., 1997;
Lahti et al., 2001).

The ketamine-induced preclinical model of schizophrenia generates robust
cognitive impairments as demonstrated by tasks probing working memory and
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the suppression of prepotent responses to stimuli (Tsai et al., 1995; Olney et al.,
1999; Javitt, 2009). Reduced cognitive function is considered to be the most
debilitating aspect of schizophrenia as the severity of these symptoms directly
relates to the patient’s quality of life and current pharmaceutical interventions
provide minimal improvement (Elvevag and Goldberg, 2000; Goldman-Rakic et
al., 2004; Goeree et al., 2005; van Os and Kapur, 2009). Non-human primates
also show similar cognitive deficits following systemic subanaesthetic doses of
ketamine as patients with schizophrenia in a number of behavioural tasks (Condy
et al., 2005; Stoet and Snyder, 2006). An example is the anti-saccade paradigm,
which requires the inhibition of a prepotent pro-saccade towards a flashed
peripheral stimulus in favour of the generation of a saccade away from the
stimulus towards the opposite direction (Everling and Fischer, 1998; Munoz and
Everling, 2004). Following ketamine injections, non-human primates exhibit
increased reaction times and error rates on anti-saccade trials (Condy et al.,
2005). These impairments seem to mimic the deficits observed in patients with
schizophrenia (Fukushima et al., 1988; McDowell et al., 2002) and patients with
prefrontal cortex (PFC) lesions (Guitton et al., 1985; Pierrot-Deseilligny et al.,
1991).

The behavioural profile of cognitive deficits following subanesthetic doses of
ketamine has been well documented, however, the neural mechanisms in the
primate PFC responsible for these changes are still unknown. Although rodent
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studies have reported an increase in frontal cortex neural activity following acute
ketamine administration (Jackson et al., 2004; Homayoun and Moghaddam,
2007), rodents lack a granular PFC which is characteristic for lateral, ventral,
medial, and frontopolar prefrontal areas in primates (Povinelli and Preuss, 1995;
Preuss, 2000; Wise, 2008). To directly investigate the effects of ketamine on
task-selective neural activity in the primate lateral PFC, we recorded single
neuron activity in macaque monkeys before and after the administration of
subanesthetic doses of ketamine during the performance of randomly interleaved
pro- anti-saccade trials.

2.2 Materials and Methods
All experiments were performed in accordance with the Canadian Council of
Animal Care policy on the use of laboratory animals and all procedures were
approved by the Animal Use subcommittee of the University of Western Ontario
Council on Animal Care (Appendix A). Two male rhesus monkeys (Macaca
mulatta) weighing 7 kg (Monkey O) and 10 kg (Monkey W) participated in the
study. Both animals had a plastic head restraint and plastic recording chambers
implanted above their lateral PFC as previously described by our laboratory
(Johnston and Everling, 2006b). Animals received analgesics and antibiotics
postoperatively and were closely monitored by a university veterinarian.
Following implantation surgery, we obtained anatomical MR images of both
monkeys using an actively shielded 7 Tesla 68-cm horizontal bore scanner
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(Varian, Yarnton, UK) and a Siemens AC84 gradient subsystem (Erlangen,
Germany). Plastic grids filled with betadine were inserted into the recording
chambers during the scan which allowed for precise electrode targeting and
subsequent reconstruction of recording locations.

2.2.1 Behavioural Task
Both animals were trained on rule-visible and rule-memorized variants of
the pro/anti-saccade task (Figure 2.1). The rule for the current trial was
presented following an initial 100 msec fixation period by changing the central
white fixation spot to either green or red, with each color indicating whether the
animal had to perform a pro-saccade (green fixation cue) or anti-saccade (red
fixation cue) in response to the ensuing peripheral stimulus. On rule-visible trials,
a peripheral stimulus appeared 8° to either the left or right following a 1000-1200
msec fixation period on the rule cue. To challenge the animal’s working memory,
the rule-memorized trials presented the rule cue for only 200 msec, after which
the color of the cue returned to white for 800-1000 msec. Following this delay
period, the peripheral stimulus was presented in a manner identical to the rulevisible trials. To obtain a juice reward, the animal was required to look to the
correct target location within a 8° circular window. On pro-saccade trials, this
required a saccade towards the peripheral stimulus, whereas on anti-saccade
trials, the correct target location was diametrically opposite of the peripheral
stimulus. Every block performed consisted of a pseudo-randomized ordering of
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Figure 2.1: Experimental paradigm. A, Rule-visible task. Each trial began with an FP
signaling, by its color, a prosaccade or antisaccade trial. A stimulus then appeared either 8° to
either the left or right. B, Rule-memorized task. Same as A, but the color of the FP changed to
white 800-1000 ms before stimulus presentation. This required the monkey to memorize the
task rule.
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the eight trial variants: pro-saccade left and right; anti-saccade left and right; with
each of these four conditions appearing as either rule-visible or rule-memorized.
Error trials were not repeated. The animals’ eye positions were recorded and
digitized at 120Hz using an ISCAN infra-red pupillary tracking system (ISCAN
Inc., Woburn, MA).

2.2.2 Multi-electrode recording
Each behavioural testing session was accompanied by electrophysiological
recordings from the left or right lateral PFC in monkey O and the left lateral PFC
in monkey W. Initial recordings were performed with twenty screw minimicrodrives (Miller laboratory, MIT, Boston, MA), each equipped with two
tungsten electrodes (FHC Inst., Bowdoinham, ME). Neural activity was combined
with performance data and eye position data into a single recording file using a
multi-acquisition processor (MAP) system (Plexon Inc., Dallas, TX). Recorded
neurons were sorted off-line using 2-D and 3-D principal component analysis. In
later recording sessions, we used a custom-designed semi-chronic screw
microdrive recording system which contained 32-recording electrodes and 2
reference electrodes (Neuronitek, London, Ontario). Initial insertion of the semichronic drive consisted of lowering individual electrodes through both a thin
silicone membrane and the animal’s dura until stable units were isolated on a
maximal number of channels. Each subsequent recording day only required
reconnecting the 32-channel headstage (Plexon Inc., Dallas, TX) and minimal
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depth adjustments to isolate new units to record for that day’s experimental
session. The microdrive system remained implanted for two weeks before it was
removed for cleaning and maintenance.

2.2.3 Drug administration
Each experimental session began with a 15-minute period of baseline
activity during which the animal performed approximately 200-250 trials in a
pseudo-randomized order. Both animals were trained extensively at the task and
performed at a <20% error rate during these pre-injection periods. After 15
minutes of trials, the experiment was briefly paused and the animal received a
single intramuscular injection of ketamine (0.4mg/kg Monkey O; 0.8mg/kg
Monkey W) diluted in sterile saline to 0.4 ml into their right triceps brachii muscle.
The injection process only interrupted the animal’s experimental session for less
than 15 seconds after which the monkeys would continue the behavioural task.
We previously performed titration experiments with each monkey to determine
animal-specific concentrations of ketamine (between 0.2mg/kg and 1.0mg/kg) for
the experiment, as these values have previously been found to elicit cognitive
deficits with minimal anaesthesic effects (Condy et al., 2005). Monkey W had
more exposure to ketamine prior to this study for surgeries and routine veterinary
procedures and developed a greater tolerance to the drug (Pouget et al., 2010).
The behavioural effects of ketamine became apparent after approximately 5
minutes (50-75 trials). Control experiments involving the intramuscular injection
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of saline only were also performed. No changes in behavior (error rates and
reaction times) or single neuron activity between the pre-injection and postinjection periods were observed (data not shown here). Experimental sessions
were separated by at least 4 days to ensure the ketamine had a sufficient washout period and thus avoid cumulative dosing effects.

2.2.4 Data Analysis
Behavioural data was calculated with the pre-injection periods defined as 15
minutes prior to injection and the post-injection period defined as 5 minutes after
injection until 25 minutes after injection, as this was the time period that displayed
the strongest behavioural effects of the drug. Directional errors were trials in
which the animal made a saccade in the opposite direction of a correct response
(anti-saccade on a pro-saccade trial and vice versa). No response trials were
those in which the animal maintained fixation during the response period, while
fixation errors consisted of trials in which the animal did not maintain fixation until
the stimulus onset. Significance was calculated between pre-injection and postinjection values for each category using paired t-tests. Later, time-course
behavioural data was calculated by combining all experimental sessions for both
monkeys and sorting the data into 5 minute bins for error rates and saccadic
reaction times. A one-way analysis of variance (ANOVA) followed by a post-hoc
Dunnett’s test was used to probe each trial type for significant differences
between the animal’s pre-injection performance and their performance at each
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binned time-point. For the analysis of neural data, we included correct and
directional error trials. The calculation of indexed values for the change in each
neurons discharge frequency included neural activity from the entire trial period
defined as 1000 msec preceding stimulus presentation until 500 msec after
stimulus presentation.

Neurons were subjected to further analysis to highlight

changes in task-selectivity following ketamine administration. Task-selectivity
was calculated as (x̅

preferred

- x̅

non-preferred

)/(x̅

preferred

+x̅

non-preferred

) using the mean discharge rate

from each neuron during a pre-stimulus epoch and a stimulus/response epoch.
Preference was defined as either task preference (pro-saccade versus antisaccade) or direction preference (contralateral stimulus versus ipsilateral
stimulus). Whichever comparison exhibited a greater selectivity was used for the
pre-injection versus post-injection scatter plot defined by epoch and rule visible or
rule-memorized conditions. Statistical significance for each neuron was tested
using a Mann-Whitney U-test for changes in task selectivity caused by the
ketamine administration.

To define cells as either narrow-spiking (putative interneurons) or broadspiking neurons (putative pyramidal neurons), we calculated mean trough to peak
times for each neuron’s extracellular waveform and constructed a histogram of
the resulting values as previously described (Johnston et al., 2009). In
accordance with this previous study, which used the same recording system and
the same type of microelectrodes, we defined neurons with waveform duration
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shorter than 270 µsec as narrow-spiking neurons and any neurons with
waveform durations longer than 270 µsec this as broad-spiking neurons.

Finally, a sliding receiver operating characteristic (ROC) curve was
computed using the neurons that were shown to exhibit selectivity in either of the
two epochs so that any differences in the significance of task-selectivity across
the entire trial period both pre- and post-injection would be apparent. The ROC
value was calculated using a sliding 100 msec window beginning 1000 msec
before peripheral stimulus onset, advancing in 1 msec increments, and extending
500 msec beyond stimulus presentation. Significance cutoff values for the 5th
and 95th percentile were calculated using a bootstrap method (Koval et al.,
2011).

2.3 Results
2.3.1 Behavioural deficits
Both animals displayed acute increases in response errors, fixation errors,
and no response trials when attempting to perform both pro- and anti-saccade
trials following ketamine administration (Figure 2.2A). The effect lasted
approximately 20 minutes in monkey O and 35 minutes in monkey W, with
performance returning to pre-injection error rates afterwards in monkey O. Error
rates decreased in monkey W over time after the initial ketamine effect, but never
returned to pre-injection levels in the timespan of each experimental session. The
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Figure 2.2: Behavioural effects of ketamine administration. A, Effect of ketamine on the directional
error rates (blue bars), response rates (green bars), and fixation error rates (red bars). Darker
shaded foreground bars represent pre-injection values and lighter background bars are postinjection values. Data for Monkey O was averaged from 8 experiment sessions; data for Monkey
W was averaged from 10 experiment sessions. B, Effect of ketamine on saccade reaction times.
Same format as A with blue bars representing saccade reaction times on correct trials and red
bars representing saccade reaction times on (directional) error trials.
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increased error rate on pro-saccade trials for both rule-visible and rulememorized conditions reached a maximum of 10% in Monkey O and 30% in
Monkey W. Ketamine caused a much stronger effect on the anti-saccade task in
Monkey O, with response errors increasing 3-fold to 30% in the rule-visible task
and to almost 60% in the rule-memorized task.

Error rates on the anti-saccade task highlighted the additional challenge that
the rule-memorized paradigm introduced. Both monkeys made more errors in the
rule-memorized condition than in the rule-visible condition. A similar separation
between rule-visible and rule-memorized tasks was not observed on the prosaccade task for either monkey. These changes were accompanied by a weak
post-saccade nystagmus, similar to those reported in previous studies involving
ketamine and saccadic eye movements (Radant et al., 1998; Condy et al., 2005;
Shen et al., 2010).

Saccade reaction times (SRTs) were also increased across all conditions in
both animals (Figure 2.2B). When analyzing the SRT for error trials only, we
found that these were also increased and that the errors being made were not
express saccades (Fischer et al., 1984). Ketamine had a similar lengthening
effect on SRTs of both correct and error responses.

2.3.2 Ketamine increases activity but decreases task selectivity of PFC neurons
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We recorded the activity of a total of 115 neurons in the lateral PFC from
two monkeys (97 from O, 18 from W) in 18 recording sessions in which we
injected subanesthetic doses of ketamine (Figure 2.3). Figure 2.4 illustrates the
effect of ketamine on a single PFC neuron. Pre-injection (left panel), the neuron
exhibited higher levels of activity prior to peripheral stimulus onset on prosaccade trials than on anti-saccade trials. These rule-related differences were
present at the time of stimulus presentation on both rule-visible (Figure 2.4A, left
panel) and rule-memorized trials (Figure 2.4B, left panel). In the post-injection
period, the neuron displayed an overall increase in activity and a decrease in
rule-selectivity at the time of stimulus presentation, which was especially evident
on rule-memorized trials (Figure 2.4B, right panel).

Figure 2.5 shows a scatter plot comparing indexed values of the change in
the overall neural activity with indexed values of the change in the task selectivity
of each cell. A significant majority of neurons (n=75, 65%) were found to be
located in the lower right quadrant, indicating an increase in neural activity but a
decrease in task selectivity (chi-squared test, p<0.001). Calculations were also
performed to define each neuron as either narrow spiking (filled symbols, n=20)
or broad spiking (hollow symbols, n=95) neural activity, but there appeared to be
no difference between the two groups in their distribution across the scatter plot.

To further examine the effects of ketamine on neural activity, we analyzed
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Figure 2.3: MRI reconstruction of recording locations. L, left hemisphere; R, right hemisphere; m,
medial; a, anterior; p, posterior; l, lateral.
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Figure 2.4 (previous page): Effect of ketamine on a single PFC neuron. The neuron was recorded
from monkey O in the dorsal bank of the principal sulcus in the right hemisphere. A, Activity on
rule-visible trials. B, Activity on rule-memorized trials. Upper panel shows a raster plot with each
dot indicating the time of an action potential relative to stimulus presentation, and each row
represents one trial.
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Figure 2.5: Effect of ketamine on change in discharge rate and change in task selectivity. Scatter
plot depicts the change in discharge rates of neurons (interval from 1000 msec before to 500 msec
after stimulus onset) after ketamine injection on the x-axis and the change in task selectivity (same
analysis interval as x-axis) on the y-axis. Circles indicate neurons recorded from Monkey O,
squares indicate neurons recorded from Monkey W, filled represent narrow-spiking neurons, and
hollow points represent broad-spiking neurons.
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mean discharge rates during the pre-stimulus period (500 msec before to
stimulus onset) with a three-way ANOVA with the factors RUL (pro-saccade or
anti-saccade), MEM (rule-visible or rule-memorized), and DRUG (pre-injection
and post-injection). This analysis showed that the factor DRUG had the strongest
effect on pre-stimulus activity, with ~60% (n=69) of neurons showing significant
differences in activity between pre- and post-injection periods (Figure 2.6A).
Further, 35 neurons (33 from Monkey O, 2 from Monkey W) displayed interaction
effects of DRUG with MEM and/or RUL. Next, we examined the effects of
ketamine on neural activity during the stimulus/response period (defined as the
period 100 msec to 400 msec following stimulus onset) with a three-way ANOVA
with the factors DIR (contralateral or ipsilateral stimulus location), RUL (prosaccade or anti-saccade), and DRUG (pre-injection and post-injection). The
results are shown in Figure 2.6B. Overall, 40% (n=46) of PFC neurons showed a
main effect of DRUG. In addition, 49 neurons (43 from Monkey O, 6 from Monkey
W) showed significant interactions of DRUG with DIR and/or RUL. For the
remainder of the analysis, we focus on those PFC neurons that exhibited
interaction effects of DRUG (pre- versus post-ketamine injection) during the prestimulus or stimulus/response period.
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Figure 2.6: Results of three-way ANOVA on differences in neural activity. A, Results during prestimulus epoch. B, Results during stimulus/response epoch. RUL: rule (pro-saccade versus antisaccade); MEM: memory condition (rule visible versus rule memorized condition); DIR: direction
(ipsilateral versus contralateral stimulus location) DRUG: ketamine status (pre-injection versus
post-injection).
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2.3.3 Ketamine-induced decrease in neural task selectivity is synchronous with
behavioural changes
Figure 2.7 shows the time-course of the behavioural changes as well as the
task-selectivity of these PFC neurons during the recording sessions. Shortly after
ketamine-administration, error rates (Figure 2.7A) and SRTs (Figure 2.7B)
significantly increase from pre-injection levels. Following the same time course,
task-selectivity (Figure 2.7C) decreased during the pre-stimulus period (dashed
line) and the stimulus/response period (solid line). For each of the neurons
selected from the ANOVAs we calculated a pre-injection and post-injection
selectivity index for the pre-stimulus (Figure 2.8A) and stimulus/response period
(Figure 2.8B). The population of neurons exhibited a significant decrease in
memory-selectivity (rule-visible versus rule-memorized) (p<0.001, Wilcoxonsigned rank test) and rule-selectivity (pro- versus anti-saccade) (p<0.01,
Wilcoxon-signed rank test) during the pre-stimulus period and in rule- (p<0.001,
Wilcoxon-signed rank test) and direction-selectivity (contra- versus ipsilateral)
(p<0.001, Wilcoxon-signed rank test) during the stimulus/response period.
Neurons were again delineated as either narrow-spiking neurons (filled symbols)
or broad-spiking neurons (hollow symbols). Both groups of neurons showed a
reduction in task selectivity following ketamine injection.
If the decrease in performance is related to the decrease in task selectivity
of prefrontal neurons following ketamine administration, one would expect that
task-selectivity would be higher on correct trials than on error trials during this
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Figure 2.7: Time course of ketamine administration. A, Transient increase of error rates in prosaccade (blue lines) and anti-saccade trials (red lines) in rule visible (solid lines) and rule
memorized (dashed lines) conditions. B, Transient increase in saccade reaction times, same
format as A. C, Reduction of task-selectivity following ketamine administration. Task-selectivity
was calculated for significant neurons for the pre-stimulus (dashed line) and stimulus/response
(solid line) epochs. Time of ketamine injection is indicated by a vertical dashed line.
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Figure 2.8: Effects of ketamine on task-selectivity. A, Task-selectivity for the individual 35 neurons
is plotted during the pre- injection period against task-selectivity during the post-injection period.
Rule indicates neurons (squares) that showed maximal task-selectivity between pro- and antisaccades. Memory indicates neurons (circles) that showed maximal task-selectivity between the
rule-visible and rue-memorized conditions. Dashed line, unity line (slope =1). B, Same as A but for
the 49 neurons in the stimulus/response epoch. Rule indicates neurons (squares) that showed
maximal task-selectivity between pro- and anti-saccades. Direction indicates neurons (circles) that
showed maximal task-selectivity between ipsilateral and contralateral stimulus presentations. Solid
points in both plots represent narrow spiking neurons, hollow points represent broad spiking
neurons.
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post-injection period. We tested this prediction by first identifying the preferred
and non-preferred condition for each neuron (highest and lowest discharge rate,
respectively) during the pre-injection period and then comparing task-selectivity
following ketamine injection between correct trials and error trials. Neurons that
were recorded from sessions in which the animal completed fewer than 5 of any
task type correctly were excluded from this analysis. In both the pre-stimulus
period (Figure 2.9A) and the stimulus/response period (Figure 2.9B), neurons
showed a significantly lower task selectivity during erroneous trials than correct
trials (p<0.01, Wilcoxon-signed rank test). This analysis demonstrates that
prefrontal task-selectivity during the pre-stimulus and stimulus/response period is
correlated with the animals’ task performance.

To illustrate the changes in task-selectivity following ketamine injection, we
determined for each neuron that displayed interaction effects of DRUG during the
pre-stimulus or stimulus/response period the neuron’s preferred task (highest
discharge rate) and non-preferred task (lowest discharge rate) during the preinjection period and constructed mean population activity plots across the trial
both before (blue lines) and after ketamine administration (red lines) (Fig 2.10).
Although the mean discharge rate increased across the entire trial, the
differences between the preferred (solid lines) and non-preferred condition
(dashed lines) were reduced considerably following ketamine injection.
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Figure 2.9: Changes in task-selectivity for error trials and correct trials. Change in taskselectivity of neurons during trials completed correctly after ketamine administration is
plotted on the x-axis while changes in task-selectivity of neurons during error trials is plotted
on the y-axis. A, Differences of correct trials versus error trials during the pre-stimulus
epoch. Data points below the unity line (dashed line) indicate a greater loss in task
selectivity during error trials. B, Differences of correct trials versus error trials during the
stimulus/response epoch, same format as A. Solid points in both plots represent narrow
spiking neurons, hollow points represent broad spiking neurons.
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Figure 2.10: Effects of ketamine on population activity of task-selective neurons. In both rulevisible A and rule-memorized conditions B, the population activity show a large separation
between the preferred and non-preferred condition before ketamine administration. This selectivity
is reduced after ketamine.
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Lastly, in order to highlight the importance of both epochs to our study, we
constructed ROC curves testing task selectivity significance levels for rule-visible
(Figure 2.11A) and rule-memorized (Figure 2.11B) tasks. The pre-stimulus
period displayed multiple timepoints during which the selectivity achieved
significance, however the strength of task selectivity in the stimulus/response
period was much more prominent. The ROC values became non-significant
following ketamine administration during both epochs.

2.4 Discussion
The ability of ketamine to induce a schizophrenia-like endophenotype was initially
attributed to the antagonism of NMDA receptors in the PFC and an assumed
downregulation of glutamatergic activity in this area (Krystal et al., 1994; Malhotra
et al., 1996). Electrophysiological studies in rodents, however, have shown that
acute, subanaesthetic doses of ketamine induce hyperactivity in the frontal cortex
while still producing the cognitive deficits required for a model of this disease
(Jackson et al., 2004; Homayoun and Moghaddam, 2007). Our results confirm
this finding in the lateral PFC of nonhuman primates and demonstrate that
subanaesthetic doses of ketamine reduce task-selectivity of PFC neurons. Our
findings suggest that an increase in activity may be impairing task-selective
outputs from the PFC by decreasing the task-selectivity of neurons and thus
reducing the ability of the PFC to exert cognitive control.

83

0.58

0.58

0.56

0.56

0.54

0.54

ROC Value

B 0.60

ROC Value

A0.60

0.52

0.52

0.50

0.50

0.48

0.48

0.46

0.46

0.44

0.44

0.42

0.42

-1000 -800 -600 -400 -200

0

200

400

Time from stimulus onset (msec)

-1000 -800 -600 -400 -200

0

200

400

Time from stimulus onset (msec)

Figure 2.11: ROC curve of task-selectivity before and after ketamine administration. A, ROC
values for rule visible trials. Pre-injection (blue solid line) and post-injection (red solid line) task
selectivity ROC values with accompanying 5% and 95% (dashed lines) significance cutoff values
as calculated by bootstrap analysis. B, ROC values for rule memorized trials, same format as A.
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2.4.1 Ketamine impairs pro- and anti-saccades
A previous study that examined the behavioural consequences of acute
ketamine administration in green monkeys found a dose-dependent increase in
reaction times for both pro- and anti-saccades (Condy et al., 2005). Condy and
colleagues (2005) tested pro- and anti-saccade trials in separate blocks and
reported that ketamine increased errors by up to 60-70% on anti-saccade trials,
whereas it did not impair the performance of pro-saccade blocks. Our data
confirm the increases in SRTs and increased errors on anti-saccade trials
following subanaesthetic doses of ketamine but also show that ketamine impairs
the performance on pro-saccade trials when these are randomly interleaved with
anti-saccade trials. Similar increases in SRT and error rates have been reported
in a cued task-switch paradigm following ketamine administration (Stoet and
Snyder, 2006).

The increased error rates by ketamine on anti-saccade trials have been
interpreted as a loss of behavioural inhibitory control over the pre-potent
stimulus-triggered saccade, potentially by interrupting dorsolateral PFC function
(Condy et al., 2005). Our data do not support this hypothesis. While ketamine did
increase the error rate on anti-saccade trials, it also led to a greater number of
errors on pro-saccade trials, i.e. the monkeys generated anti-saccades on prosaccade trials. The effects were prolonged on anti-saccade trials that contained a
working memory component and following ketamine administration both monkeys
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frequently discontinued fixation or did not respond. Furthermore, the errors on
anti-saccade trials had reaction times well-above the range of automatic express
saccades (80-125 msec) which are directly triggered by the incoming visual
stimulus in the superior colliculus (Dorris et al., 1997; Everling et al., 1999).
Interestingly, although often described as automatic or prepotent responses,
errors of schizophrenic patients in the anti-saccade task are typically not in the
express saccade range (Lencer, personal communication). We propose that
ketamine increased errors on pro- and anti-saccade trials because it impaired the
animal’s ability to selectively maintain, or apply the two task sets. This type of
deficit is common in patients with frontal lobe damage and has been termed goal
neglect (Duncan et al., 1996).

Duncan and colleagues have suggested that

frontal and possibly parietal brain areas are involved in organizing relevant facts,
rules, and requirements into a “task model” (Duncan et al., 2008). This idea is
supported by many experiments on single neurons in the primate lateral PFC in
behaving monkey. These studies have found that a large proportion of PFC
neurons code various aspects of whatever task a monkey has been trained to
perform (stimuli, responses, rules, rewards) and that the coding changes when
the animal must perform a different task (Hoshi et al., 1998; Rainer et al., 1998;
White and Wise, 1999; Asaad et al., 2000; Everling and DeSouza, 2005; Everling
et al., 2006; Johnston and Everling, 2006a).

2.4.2 Ketamine increases activity of PFC neurons

86
To directly test whether ketamine interfered with the coding of task-relevant
information in the PFC, we recorded the activity of single neurons in the lateral
PFC before and after the administration of ketamine. Rodent studies showed that
subanesthetic, systemic doses of ketamine are capable of increasing frontal
cortex metabolic (Duncan et al., 1999; Dawson et al., 2013) and neural discharge
activity (Jackson et al., 2004; Homayoun and Moghaddam, 2007). When
administered to human subjects, acute doses of ketamine can also increase
neural activity as measured by fMRI in working memory tasks (Honey et al.,
2004) and regional cerebral blood flow (Holcomb et al., 2005). Here we found
that subanaesthetic, systemic administration of ketamine in the behaving primate
also acutely increases the activity of neurons in the lateral PFC. While the
behavioural findings alone provide support for a ketamine-centric preclinical
model of schizophrenia, there may be paradoxical reversal when the model is
compared to the disease at the neurophysiological level.

The glutamate model of schizophrenia posits that many of the disease’s
symptoms (including the cognitive deficits) arise from a hypofrontality and
hypoglutamatergic state in the PFC (Olney et al., 1999). While chronic
administrations of NMDA antagonists can induce a similar hypofrontality (Morris
et al., 2005; Mouri et al., 2007), the present study in primates and previous
studies in rodents (Jackson et al., 2004; Homayoun and Moghaddam, 2007)
found that acute treatments of NMDA antagonists increase frontal activity. It
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should be noted here that the hypofrontality in the PFC of schizophrenic patients
is inferred from EEG, PET, and fMRI studies but that it is unknown whether the
activity of single PFC neurons is actually reduced in schizophrenic patients
(Ragland et al., 2007; Marek et al., 2010).

It has been suggested that ketamine acts preferentially on PFC
interneurons and therefore produces a localized disinhibition of pyramidal
neurons (Homayoun and Moghaddam, 2007). This specificity for GABAergic
interneurons parallels postmortem studies in humans that found patients with
schizophrenia often exhibited reduced levels of interneuron markers (Benes et
al., 1991; Lewis et al., 1999). However a more recent study has found that this
selectivity may not be this straightforward, as NMDA antagonists have been
shown to exhibit a lowered affinity for fast-spiking interneurons (Rotaru et al.,
2011). This newer data supports the hypothesis that the mechanism behind the
increased activity in the PFC may be an effect of NMDA receptor blockade in
regions of the brain that have inhibitory projections to the PFC (Kiss et al., 2011)
since localized injections of NMDA antagonists into the PFC were unable to
increase PFC glutamatergic activity in rodents (Suzuki et al., 2002; Lorrain et al.,
2003).

To test whether ketamine had different effects on interneurons and

pyramidal cells, we separated the recorded neurons based on their spike widths
(Mitchell et al., 2007; Johnston et al., 2009). The results suggest that systemic
ketamine administration had similar effects on the two groups, however, these
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results should be interpreted with caution because of the low number of putative
interneurons.

One might have expected that an increase in activity would increase taskselectivity of PFC neurons, but our data clearly show that the increase in activity
was accompanied by a decrease in selectivity for the pro-/anti-saccade task and
response direction. Moreover, we could show that task-selectivity was lower on
error trials than correct trials following ketamine administration. This finding
demonstrates that task-selectivity of PFC neurons correlates with the animal’s
performance. This non-discriminatory increase in neural activity - which
decreases task-selectivity - would decrease the task-selective signals that the
PFC sends to other areas like the superior colliculus (Johnston and Everling,
2006a, 2009). Without these task-selective signals, the flow of task-related
activity in the saccade-generation network may be impaired. Interestingly, an
increased prefrontal activation has recently been shown using fMRI in the
dorsolateral PFC of schizophrenic patients during the performance of pro- and
anti-saccades (Fukumoto-Motoshita et al., 2009).

It should be noted that the behavioural deficits in task performance are
much stronger in this study that induced PFC hyperactivity than they were in a
previous study, where we induced acute PFC hypoactivity via surgically
implanted cryoloops in the principle sulcus (Koval et al., 2011). Animals
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performing the anti-saccade task exhibited only mild impairments in the rulevisible task when the principal sulcus was cryogenically deactivated, however,
performance in the rule-memorized task was impaired to a much greater degree.
The strong impairments on the rule-visible task following ketamine injections
seen here may have been caused by a disruption of task-selectivity in the ventral
PFC, which is critical for cued stimulus-response associations (Bussey et al.,
2001, 2002; Buckley et al., 2009).

Due to the systemic administration method, we cannot rule out that the
behavioural effects by ketamine on pro- and anti-saccades are mediated by
areas outside of the lateral PFC, as task-selectivity for pro- and anti-saccades
has also been found in the globus pallidus, thalamus, lateral intraparietal area,
frontal eye fields, and supplementary eye fields (Schlag-Rey et al., 1997; Gottlieb
and Goldberg, 1999; Everling and Munoz, 2000; Zhang and Barash, 2000; Ford
and Everling, 2009; Watanabe and Munoz, 2009; Yoshida and Tanaka, 2009;
Kunimatsu and Tanaka, 2010). In fact, it has previously been demonstrated that
ketamine can have a significant effect on superior colliculus neurons (Populin,
2005), however that study used doses of ketamine well within the anaesthetic
range.

In summary, our data show that ketamine increases the activity of PFC
neurons in primates, while it reduces at the same time task-selectivity in these

90
neurons. The non-discriminate increase in PFC activity may mask the efferent
task-related signal required by downstream cortical and subcortical regions for
correct task performance, effectively exporting irrelevant noise.
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Chapter 3

NMDA receptor antagonist ketamine impairs
action-monitoring activity in the prefrontal cortex
A version of Chapter 3 is published as K Skoblenick and S Everling, (2014)
NMDA receptor antagonist ketamine impairs action-monitoring activity in the
prefrontal cortex. The Journal of Cognitive Neuroscience.

3.1 Introduction
Everyday life requires the ability to detect when one’s actions are
erroneous and to correct them if necessary. Electrophysiological recordings in
nonhuman primates have shown that both lateral prefrontal cortex (LPFC) and
anterior cingulate cortex (ACC) neurons are active when this action monitoring is
required (Niki and Watanabe, 1979; Ito et al., 2003; Amiez et al., 2005).
According to one prominent theory, the ACC detects the presence of conflict and
monitors the outcome of actions and then provides a signal to areas like the
LPFC, which then adjust the level of cognitive control for future actions (Botvinick
et al., 2001; Carter et al., 2001; Miller and Cohen, 2001; Yeung et al., 2004;
Carter and van Veen, 2007). The strongest support for a role of the ACC in action
monitoring comes from studies of the error-related negativity (ERN) in human
subjects (Yeung et al., 2004), an event-related potential that occurs after errors in
reaction time tasks. However, the LPFC clearly interacts with the ACC in action
monitoring as LPFC lesions abolish differences between error-trial ERN and
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correct trial activity and affect corrective behaviour after a response error
(Gehring and Knight, 2000).

Blunted brain responses to errors are characteristic for schizophrenic
patients as indicated by reduced error-related scalp potentials and altered
activation in the LPFC and ACC on response error trials in patients (Gehring et
al., 1995; Kopp and Rist, 1999; Polli et al., 2005; Polli et al., 2008; Mathalon et
al., 2009). In fact, it has been proposed that failures in self-generated action
monitoring and internal monitoring of speech output contribute to delusions of
alien control (Frith and Done, 1989) and formal thought disorder (Feinberg and
Guazzelli, 1999), respectively. Deficits in action and internal speech monitoring
(Stone et al., 2011), together with other positive, negative, and cognitive
symptoms typical for schizophrenia, also occur following acute subanesthetic
doses of ketamine (Luby et al., 1959; Domino et al., 1965; Gunduz-Bruce, 2009),
a noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist. Therefore,
it has been suggested that NMDAR dysfunction may underlie self-monitoring
deficits and psychotic symptoms in schizophrenia (Stone et al., 2011) and that
ketamine is a promising pharmacologically induced model of schizophrenia in
nonhuman primates (Condy et al., 2005; Skoblenick and Everling, 2012;
Blackman et al., 2013; Gil-da-Costa et al., 2013).
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A link between prefrontal cortex function and the action of ketamine has
been found in rats (Jackson et al., 2004) and nonhuman primates (Skoblenick
and Everling, 2012), where low systemic doses of NMDAR antagonists potentiate
the firing of most neurons. We have shown recently that LPFC neurons also lose
their selectivity for the task rule following administration of a single subanesthetic
dose of ketamine (Skoblenick and Everling, 2012), consistent with the hypothesis
that NMDAR-antagonists disrupt frontal lobe function by decreasing the signal-tonoise ratio of LPFC neurons (Jackson et al., 2004).

Here we examined the effects of ketamine on post-response activity and
inter-trial activity in the LPFC by recording single neuron activity in macaque
LPFC neurons before and after the injection of a subanesthetic dose of ketamine,
while the animals performed randomly interleaved trials of prosaccades and
antisaccades (Munoz and Everling, 2004). Prosaccade trials required the animals
to simply look towards a peripheral stimulus, whereas antisaccade trials required
the animals to suppress a saccade towards the stimulus and instead to look
away from it to the opposite direction. Antisaccade errors, which are elevated in
patients with prefrontal lesions (Guitton et al., 1985; Pierrot-Deseilligny et al.,
1991; Ploner et al., 2005), schizophrenia patients (Fukushima et al., 1988;
Sereno and Holzman, 1995), and in nonhuman primates following ketamine
administration (Condy et al., 2005; Skoblenick and Everling, 2012), elicit robust
error-related scalp potentials in healthy human subjects (Nieuwenhuis et al.,
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2001). Analysis of error-related activity was restricted to antisaccade trials since
nonhuman primates (Bell et al., 2000), like human subjects (Dafoe et al., 2007),
produce few prosaccade errors in this paradigm.

3.2 Materials and Methods
We collected data in two male adult macaque monkeys (Macaca mulatta)
following guidelines of the Canadian Council of Animal Care policy and a protocol
approved by the Animal Use Subcommittee of the University of Western Ontario
Council on Animal Care. All experimental procedure have been described in
detail previously (Skoblenick and Everling, 2012).

3.2.1 Behavioral Task
Monkeys were seated in a primate chair within a sound-attenuating
chamber with their heads restrained and a juice-spout placed at their mouth for
computer-controlled reward delivery. Stimuli were presented on a 21'' CRT
monitor 42 cm in front of the animals. Behavioural control and stimulus
generation were accomplished with the CORTEX and MonkeyLogic software
package, while eye movements were recorded at 120 Hz with an infrared video
eye tracker (ISCAN, Boston, MA). Each trial started with the presentation of a
white fixation point (FP), which changed colour to either red or green in a
pseudorandom order after an initial 100 ms fixation period. In monkey O, a red
FP instructed an antisaccade and a green FP a prosaccade in response to the
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ensuing peripheral stimulus. The mapping was reversed for monkey T. In half of
the trials, the initial central FP changed back to white after a 200 ms period. This
manipulation was included for a previous study in which we investigated
ketamine effects on working memory for the task rule (Skoblenick and Everling,
2012). A peripheral stimulus appeared 8° to either the left or right following a
1000-1200 ms fixation period. To obtain a juice reward, the animal was required
to look to the correct target location within a target window, i.e. towards the
stimulus on prosaccade trials and diametrically opposite of the peripheral
stimulus on antisaccade trials. The reward was delivered as soon as the monkey
looked into target window (8° circular window in MonkeyLogic and 8°x 8° in
CORTEX). Error trials were defined as those in which the monkey performed the
incorrect saccade: a prosaccade during a trial with the antisaccade rule or vice
versa.

3.2.2 Recording Method
Extracellular recordings were conducted with a semichronic screw microdrive
system (Neuronitek, London, ON) equipped with 32 individually moveable
tungsten microelectrodes (FHC Inst., Bowdoinham, Maine), guided by anatomical
MR images to ensure targeting the area in and around the posterior principal
sulcus. Initially, all individual electrodes were lowered through both a thin silicone
membrane and the monkey’s dura until multiple neurons were well isolated on a
maximal number of electrodes. On each subsequent recording day, the 32
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channel headstage (Plexon Inc., Dallas, TX) was reconnected and electrodes
were moved to isolate new neurons for that day’s experimental session. To
ensure a relatively unbiased sampling of LPFC neural activity, we did not prescreen neurons for task-related responses. The microdrive system remained
implanted for up to 2 weeks before it was removed for cleaning and maintenance.

Data acquisition and filtering were performed with a multi-acquisition
processor (MAP) system (Plexon Inc., Dallas, TX). Recorded neurons were
sorted off-line using 2-D and 3-D principal component analysis using Offline
Sorter (Plexon Inc., Dallas, TX). Horizontal and vertical eye positions and the
occurrence of behavioural events (e.g. start of trial, onset of fixation, stimulus
presentation) were also stored in the Plexon MAP system.

3.2.3 Drug administration
Each experimental session began with a 10 min (monkey T) or 15 min
(monkey O) period of baseline activity during which the animal performed blocks
of trials in a pseudo-randomized order. After the baseline period, the experiment
was briefly paused and the animal received either a single subanesthetic
intramuscular injection of 0.4 ml ketamine (0.4mg/kg, diluted in sterile saline),
which previously has been found to elicit cognitive deficits with minimal
anaesthesic effects in rhesus monkeys (Condy et al., 2005; Stoet and Snyder,
2006; Shen et al., 2010; Blackman et al., 2013), or 0.4 ml of sterile saline into
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their right tricep brachii muscle. The injection process only interrupted the
animal’s experimental session for less than 15 sec after which the monkeys
would continue the paradigm. We recorded neural activity for at least 40 min
following ketamine or saline injection throughout these sessions.

Ketamine

injection sessions were separated by at least 4 d to avoid cumulative dosing
effects and potential neuronal injury (Liao et al., 2011). Saline injections were
performed on some of the days on which no ketamine was administered.

3.2.4 Data Analysis
Data

analysis

was

performed

using

custom-designed

software

programmed in Matlab (Mathworks). Saccade onset of the initial saccade was
defined as the time at which the horizontal velocity exceeded 30°/s after
peripheral stimulus onset and the end of the saccade was defined as the time
when the velocity fell below 30°/s. The onset of the return or correction saccade
was defined as the time when the horizontal velocity exceeded 30°/s after the
end of the initial saccade. An antisaccade error was defined as an initial saccade
toward the peripheral stimulus. Fixation breaks or no responses were not
included in error rate calculations. All trials were visually-inspected after
automatic saccade detection and corrected if necessary.

3.2.5 Effect of previous trial performance
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Several studies have reported post-error slowing of antisaccades (Polli et
al., 2006; Klein et al., 2007). For this analysis, we only included correct
antisaccade trials that were preceded by a correct response (pro- or antisaccade)
or an error (pro- or antisaccade) on the previous trial. Correct antisaccade trials
that were preceded by a broken fixation or no response trial were excluded from
this analysis. The low number of correct antisaccades that were preceded by
errors required us to pool the reaction times from all 10 sessions. To do this, we
first z-normalized the reaction times of correct antisaccades before and after
ketamine for each session and then combined the z-normalized reaction times
from the individual sessions. There were not enough trials for this analysis in the
five saline control sessions.

3.2.6 Performance-selectivity
Neurons were classified as performance-selective, based on a two-way
analysis of variance (ANOVA) on neural activity in the interval 200-700 ms after
saccade onset during the pre-injection period, evaluated at p<0.05. The factors
were Performance (correct or error antisaccades) and Saccade Direction
(ipsilateral or contralateral to recorded hemisphere). Only neurons that showed a
main effect of Performance but no significant effect of Saccade Direction and no
significant Performance x Saccade Direction interaction were classified as
performance-related. A neuron’s preferred performance was defined as the
performance (correct or error) that was associated with the maximal spiking
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activity. As a measure of performance selectivity (preferred vs. nonpreferred
performance), the selectivity index was defined as: S = (p - np) / (p + np) where p
= activity on preferred trials in the interval 200-700 ms after saccade onset; np =
activity on nonpreferred in the same interval.

3.2.7 Selectivity during intertrial period
According to several cognitive control models (Botvinick et al., 2001; Miller
and Cohen, 2001; Yeung et al., 2004; Carter and van Veen, 2007), the activity in
the LPFC is increased after response conflict or response errors to increase
cognitive control for the following trial. To test whether ketamine affected the
activity during the intertrial period, we classified neurons as outcome selective
during the intertrial period if they exhibited significant differences (t-test, p<0.05)
in the period 1500-2500 ms following saccade onset between correct and error
trials. This period was just before the fixation point was presented for the
following trial. A neuron’s preferred outcome was defined as the outcome (correct
or error) for which the neuron displayed the maximal spiking activity during this
period.

3.2.8 ROC analysis
To evaluate how well LPFC neurons could discriminate between correct
and error responses, we computed receiver operating characteristic (ROC)
values for the discharge during the performance-monitoring and the intertrial
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periods for selective neurons. An ROC analysis measures the degree of overlap
between two distributions. For each neuron, the activity on correct trials was
compared with the activity on error trials, yielding two distributions of neuronal
activity. Each point on the ROC curve was created by plotting the proportion of
the distribution with the higher mean activity against the proportion of the
distribution with the lower mean activity. To generate the entire ROC curve, the
criterion level was incremented from zero to the maximal discharge rate in 20
steps. The area under the ROC curve is a quantitative measure of the separation
of the two distributions. A value of 0.5 indicates that the two distributions
completely overlap. Values of 0 and 1.0 indicate that the two distributions are
completely separate.

3.2.9 Fano factor
As a measure of neural reliability, we computed the fano factor (variance
divided by mean) for the discharge rates during the performance-monitoring
period and the intertrial period.

3.2.10 Waveform analysis
To test whether ketamine had different effects on narrow-spiking (putative
interneurons) and broad-spiking neurons (putative pyramidal neurons), we
computed mean trough-to-peak times for the extracellular waveform of each
neuron using previously described procedures (Mitchell et al., 2007; Johnston et
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al., 2009) Based on the results of the previous study from our lab were use used
the same recording system and the same type of microelectrodes in the LPFC,
we defined neurons with waveform durations of 270 μs as narrow-spiking
neurons and any neurons with waveform durations of 270 μs as broad-spiking
neurons.

3.3 Results
We administered subanesthetic doses of ketamine in 10 experimental
sessions (5 in each monkey) and control injections of saline in 5 sessions (4 in
monkey O and 1 in monkey T), while the animals performed randomly interleaved
pro- and antisaccade trials. We recorded the activity of 343 LPFC neurons (111
in monkey O, 232 in monkey T) during the ketamine sessions and of 99 LPFC
neurons during the saline injections (51 in monkey O, 48 in monkey T).

3.3.1 Reaction times and error rates
Figure 3.1 shows the effects of ketamine and saline injections on error
rates and reaction times of prosaccades (Figure 3.1A) and antisaccades (Figure
3.1B). In line with several previous reports, both animals had longer reaction
times for antisaccades than prosaccades and made very few prosaccade errors
prior to ketamine administration, but generated a 10-20% error rate on
antisaccade trials (Amador et al., 1998; Bell et al., 2000). Following ketamine
administration (thick lines), reaction times of prosaccades (Figure 3.1A, top
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panel) and antisaccades (Figure 3.1B, top panel) increased. At the same time,
error rates on antisaccade trials (Figure 3.1B, bottom panel) and to a lesser
degree on prosaccade trials (Figure 3.1A, bottom panel) increased. Reaction
time and performance effects started about 5 min following ketamine injections.
Performance returned to pre-injection levels after about 20 min, whereas the
effects on reaction times persisted for the duration of the sessions. Saline
injections (thin lines) neither influenced reaction times nor performance of pro- or
antisaccades. For all following behavioural and neural analyses, we compared a
pre-injection period (10 min interval before injection) with a post-injection period
(5-20 min after injection).

3.3.2 Reaction times of correct responses and errors on antisaccade trials
We next examined the effects of ketamine on reaction times of correct responses
and errors separately for each monkey. Figure 3.2A shows cumulative
distributions of correct antisaccade reaction times for ketamine and saline
sessions. In monkey O (Figure 3.2, top panel) reaction times increased from 193
± 2 ms to 252 ± 5 ms (t-test, p<0.00001) following ketamine injections. No effects
were found for saline injections (196 ± 5 ms versus 198 ± 3 ms; t-test, p=0.65).
Similarly, in monkey T (Figure 3.2, bottom panel) antisaccade reaction times
increased from 188 ± 2 ms to 237 ± 4 ms (t-test, p<0.00001) after ketamine
injections. Saline injections also did not increase antisaccade reaction times in
this animal (180 ± 5 ms versus 178 ± 3 ms; t-test, p=0.18).
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Figure 3.1: Time course of ketamine and saline injections on behaviour. A, Effects of ketamine
(thick line) and saline (thin lines) injections on mean ± standard error of the mean saccadic
reaction times (top panel) and error rates (bottom panel) on prosaccade trials. The time of
injection is indicated by a vertical dashed line. B, Same as A for antisaccade trials.
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Figure 3.2: Antisaccade reaction times before and after injections. A, Cumulative distribution of
correct responses on antisaccade trials for monkey O (top panel) and monkey T (bottom panel).
Ketamine increased antisaccade reaction times in both animals. B, Cumulative distribution of error
responses on antisaccade trials monkey O (top panel) and monkey T (bottom panel). Ketamine
increased error reaction times in both animals.
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The cumulative reaction time plots in Figure 3.2B show that monkeys
mainly generated errors in the range of express saccades (Boch et al., 1984)
before ketamine injections, while post-ketamine errors had considerably longer
reaction times.

In monkey O (Fig. 3.2B, top panel), error reaction times

increased from 103 ± 4 ms to 185 ± 8 ms (t-test, p<0.00001) and in monkey T
(Figure 3.2B, bottom panel) from 96 ± 4 ms to 248 ms (t-test, p<0.00001). We
found a small increase in error reaction times following saline injections (from 87
± 1 ms to 94 ± 3 ms; t-test, p<0.05) in monkey O and no differences in monkey T
(from 199 ± 32 to 128 ±22 ms; t-test, p=0.07).

3.3.3 Behaviour after initial saccade
Next, we investigated whether ketamine had effects on the monkeys’ behaviour
after the saccade. Figure 3.3A shows the cumulative reaction times of the
saccade away from the initial antisaccade fixation location. On these correct
trials, the animals received a liquid reward immediately after the antisaccade
entered the target window (see Methods). In both monkeys, the reaction times of
return saccades did not differ between the pre-injection (solid blue line) and postinjection period (solid red line) in ketamine session (Monkey O: 398 ± 13 ms vs.
360 ± 17 ms, respectively; p=0.11; Monkey T: 981 ± 20 ms vs. 948 ± 20 ms,
respectively, p=0.24). Similarly, the reaction times of return saccades did not
differ before (dashed blue line) and after (dashed red line) saline injections
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Figure 3.3: Reaction time of the return saccade. A, Cumulative distribution of reaction times of
return saccades on correct antisaccade trials for monkey O (top panel) and monkey T (bottom
panel). There were no differences in reaction times before (blue lines) and after (red lines)
ketamine (solid lines) or saline (dashed lines) injections. B, Same as A but for return saccades
following an error on antisaccade trials. Ketamine increased the reaction times of return saccades
following a response error, rendering them similar to the reaction times following correct
prosaccades (black lines).
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(Monkey O: 429 ± 13 ms vs. 399 ± 13 ms, respectively; p=0.09; Monkey T: 1041
± 29 ms vs. 975 ± 27 ms, respectively, p=0.11).

On antisaccade error trials (Figure 3.3B) on which the animal looked
towards the stimulus and did not receive a reward, the reaction times of the
return saccades were significantly longer in the post-injection (solid red line)
compared with the pre-injection period (solid blue line) in ketamine sessions in
monkey O (730 ± 51 ms vs. 248 ± 20 ms, respectively; p=3.2 * 10-12) and monkey
T (904 ± 36 ms vs. 416 ± 37 ms, respectively; p=2.2 * 10-42). The reaction times
of return saccades after antisaccade errors were similar to the reaction times of
return saccades after correct prosaccades (solid black line) after ketamine
(Monkey O: 685 ± 51 ms; Monkey T: 1057 ± 15 ms). In both cases, the animals
looked towards the stimulus, but they were only rewarded on correct
prosaccades trials and not on antisaccade error trials. Saline injections (dashed
lines) had no effect on the reaction times of the return saccade after an error
(Monkey O: 225 ± 19 ms vs. 235 ± 33 ms, p=0.81; Monkey T: 347 ± 54 ms vs.
557 ± 96 ms, p=0.07) and the reaction times of these return saccades post saline
injections were significantly shorter than the reaction times of return saccades
after correct prosaccades (Monkey O: 445 ± 11 ms, p<0.00001; Monkey T: 1159
± 13 ms, p=2.2 * 10 -20). These findings show that ketamine did not influence the
time when monkeys made a return saccade after a correct antisaccade, but it
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significantly increased the reaction time of return saccades after an error,
rendering them similar to return saccades after correct prosaccades.

Although these data suggest that ketamine impaired the animals’ ability to
detect that they made a mistake on antisaccade error trials, it is also possible
that the presence of the stimulus on the fovea after the response errors attracted
fixation and prevented the animals from looking back. In this case, ketamine
would impair the disengagement of fixation and not performance monitoring. If
the deficit is due to an attraction to visual stimuli following ketamine, then one
would expect that errors on prosaccade trials would be corrected faster after
ketamine. Our data do not support this possibility. Monkey O made a return
saccade after 433 ± 41 ms prior to ketamine injections and after 611 ± 32 ms
post ketamine injections on prosaccade error trials (i.e. an antisaccade)
(p<0.005). The same trend was found in monkey T (300 ± 47 ms pre injection
and 451 ± 55 ms post ketamine injections). This was not significant due to the
small number of trials (5 pre ketamine and 38 post ketamine trials). Therefore the
pattern of reaction times is inconsistent with the disengagement explanation in
both animals, but it cannot be definitely ruled out due to insufficient power.
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3.3.4 Reaction times on the following trial
The reaction times of correct antisaccades were significantly longer when
they were preceded by an antisaccade error trial compared with a correct
antisaccade trials (z-scores 0.39 ± 0.15 versus -0.04 ± 0.04; p<0.005, t-test)
before ketamine was injected. These differences disappeared after ketamine
administration (z-scores 0.03 ± 0.12 versus -0.01 ± 0.05; p=0.98, t-test).

3.3.5 Performance-related neural activity
Consistent with previous reports (Niki and Watanabe, 1979), we observed
that many LPFC neurons had differences in post-response activity between
correct and error trials. Of the 343 neurons recorded during the 10 ketamine
injection sessions, 63 neurons (18.4%) showed a main effect of performance, 30
(8.6%) showed an effect of saccade direction, 16 neurons (4.6%) showed both
main effects, and 47 neurons (13.5%) showed an interaction effect. The results
were comparable for the 99 neurons that we recorded in the 5 saline injection
sessions. Here, 16 (16.2%) showed a main effect of performance, 10 (10.1%)
showed a main effect of direction, 5 (5.1%) showed both effects and 17 neurons
showed an interaction effect (17.2%). For those neurons that had a main effect of
saccade direction, there was a mild direction preference for contralateral
saccades (54% in the ketamine sessions and 60% in the saline sessions were
more active after contralateral saccades).
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For the following analyses, we defined a neuron as performance-related, if
it had a significant main effect of performance and no main effect of saccade
direction or interaction. Of the 63 performance-related neurons recorded during
the ketamine injection sessions, 44 neurons (69.8%) were more active after
errors and 19 neurons were more active after correct responses (30.2%). This
proportion was similar for the saline injection sessions, were 13 of 16 neurons
(81.3%) were more active for errors than correct responses.

Figure 3.4 shows single neuron examples of performance-related LPFC
neurons on correct and error antisaccade trials (Figure 3.4A) before (left panel)
and after the administration of 0.4 mg/kg ketamine (right panel). The neuron in
Figure 3.4B was more active after errors during the pre-injection period, whereas
the neuron in Figure 3.4C was more active after correct responses during this
period. Following ketamine, the differences in activity between correct and error
responses disappeared in both neurons. For the population of recorded neurons,
the effects were very similar for neurons that preferred errors and those that
preferred correct responses (see Table 3.1). Therefore we combined the
responses for the two types of performance-related neurons by defining each
performance-related neuron’s preferred outcome as the response (correct or
error) that yielded the maximal response during the pre-injection period.
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Figure 3.4: Schematic of correct responses and errors in the antisaccade task and single neuron
activity. A, Correct responses were defined as saccades away from the peripheral stimulus and
error responses were defined as saccades toward the stimulus. B, Activity of a single neuron in
the prefrontal cortex that exhibited increased post-response activity on error trials (red) compared
with correct trials (blue). Dots indicate the time of an action potential following saccade onset.
Each row is the activity on one trial. Superimposed are the spike density functions for correct and
error trials. C, Same as B but for a neuron that exhibited increased post-response activity on
correct trials (blue) compared with error trials (red). The differences between correct and error
trials were reduced in both neurons after administration of 0.4 mg/kg ketamine.
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Figure 3.5A shows the activity of the population of performance-related
neurons before ketamine (dashed lines) and after ketamine (solid line). The
neurons’ activity increased prior to saccade onset and began to decline 100 ms
after saccade onset for nonpreferred trials (blue dashed line). On preferred trials
(red dashed line), the activity decreased later. Following ketamine administration
(solid lines), the pre-saccade firing rates increased in the population of neurons,
consistent with the known effects of NMDAR antagonists on LPFC neurons in
primates (Skoblenick and Everling, 2012) and rodents (Jackson et al., 2004).
Ketamine did not seem to affect the activity on preferred trials following the
saccade (red solid line), but it clearly increased the activity on nonpreferred trials
(blue solid line).

To quantify these effects, we compared the activity before and after
ketamine for preferred and nonpreferred responses in the period 200-700 ms
after saccade onset. On preferred trials (Figure 3.5B), no significant effect
(p=0.30; paired t-test) was found between the activity before and after ketamine
(7.6 ± 0.8 and 8.0 ± 1.1 spikes/s, respectively). On nonpreferred trials (Figure
3.5C), performance-related activity increased from 3.9 ± 0.6 to 7.6 ± 1.1 spikes/s
(p<0.0001; paired t-test). For saline injections (Figure 3.5D), no differences in
activity were found before and after injections for preferred trials (Figure 3.5E,
11.9 ± 2.9 and 10.6 ± 2.0 spikes/s, respectively; p=0.30, paired t-test) and
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Figure 3.5: Activity of LPFC neurons with performance-selectivity. A, Mean ± within-subject
standard error of the mean spike density of the population for preferred (red) and nonpreferred
responses (blue) before (dashed lines) and after ketamine (solid lines). B, Activity levels in the
shaded region in A of individual LPFC neurons are plotted for preferred trials before ketamine
(abscissa) against the activity levels after ketamine (ordinate). Circles and squares indicate
neurons that were recorded from monkey O and monkey T, respectively. Filled symbols indicate
neurons that preferred error responses and unfilled symbols indicate neurons that preferred
correct responses. C, Same as B but for nonpreferred trials. D, E, F, Same as A, B, C but for
saline sessions.
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nonpreferred trials (Figure 3.5F, 6.5 ± 1.6 and 8.2 ± 2.4 spikes/s, respectively;
p=0.13, paired t-test).

The behavioural finding that ketamine increased reaction times of error
antisaccades raised the possibility that the ketamine effects on neural activity in
the LPFC might have been related to the different onset times of return
saccades. To test this possibility, we aligned neural activity on the onset of the
return saccade (Figure 3.6). There was no decline in neural activity before the
return saccade, ruling out the possibility that differences in reaction times caused
the differences in neural activity of LPFC neurons before and after ketamine.

3.3.5(i) Discriminability
To evaluate the effects of ketamine on the ability of neurons to
discriminate between correct and error trials, we compared the ROC values
before and after injections. For the population, the ROC value dropped from 0.73
± 0.01 to 0.53 ± 0.02 (p=6.59 * 10 -16) after the administration of ketamine (Figure
3.7A).

There was also a decrease in ROC value, i.e. in the discriminability

between correct and error trials, from 0.73 ± 0.02 to 0.64 ± 0.03 (p<0.01)
following the injection of saline (Figure 3.7B) which might be related to fatigue or
motivation effects. The reduction in ROC-value, however, was significantly larger
following ketamine compared with saline injections (-0.19 ± 0.02 versus -0.09 ±
0.03; p<0.01, paired t-test) (Figure 3.7C).
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Figure 3.6: Activity of LPFC neurons that showed performance-selectivity aligned on return
saccade onset. Mean ± within-subject standard error of the mean spike density of the population
for preferred (red) and nonpreferred responses (blue) before (dashed lines) and after ketamine
(solid lines). The activity did not decline prior to the return saccade, indicating that the ketaminemediated effects on neural activity in Fig. 4 are not due to differences in reaction times of return
saccades.
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Figure 3.7: ROC analysis of performance-related activity. A, ROC-values for performanceselective neurons are plotted before ketamine (abscissa) against ROC-values after ketamine
(ordinate). Circles and squares indicate neurons that were recorded from monkey O and monkey
T, respectively. B, Same as in A but for saline sessions. C, Distribution of changes in ROC-values
for individual neurons after ketamine (black bars) and saline (white bars) injections.
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3.3.5(ii) Reliability
While we observed changes in the neural activity after ketamine
administration, there were no differences in response variability as measured by
the fano factor before and after ketamine injections for the preferred (3.01 ± 0.17
versus 3.03 ± 0.20; p=0.98, paired t-test) or nonpreferred condition (3.06 ± 0.17
versus 3.11 ±.0.24; p=0.91, paired t-test). There were also no changes in the
fano factor for the saline sessions.

3.3.6 Narrow-spiking versus broad-spiking neurons
Of the 63 performance-selective neurons recorded during the ketamine
injections, 10 were classified as narrow spiking, i.e. putative interneurons, and 44
neurons were classified as broad-spiking, i.e. putative pyramidal neurons, based
on their waveforms (see Methods). Of the 10 narrow-spiking neurons, four were
more active after correct responses and 6 were more active after errors. Figure
3.8 shows the effects of ketamine on broad-spiking and narrow-spiking neurons.
Broad-spiking neurons exhibited no differences in activity before and after
ketamine (6.5 ± 0.8 and 6.8 ± 1.0 spikes/s, respectively; p=0.51, paired t-test) for
the neurons’ preferred condition. For the nonpreferred condition, broad-spiking
neurons increased their activity from 3.3 ± 0.5 to 6.5 ± 0.9 spikes/s (p<0.000001,
paired t-test). The responses of narrow-spiking neurons were similar.

No

significant effect (p=0.41; paired t-test) was found between the activity before and
after ketamine (13.2 ± 3.1 and 14.7 ± 4.3 spikes/s, respectively) for the neurons’
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Figure 3.8: Effects of ketamine on broad-spiking and narrow-spiking neurons with performanceselectivity. A, Mean ± within-subject standard error of the mean spike density of broad-spiking
neurons (putative pyramidal neurons) for preferred (red) and nonpreferred responses (blue) before
(dashed lines) and after ketamine (solid lines). B, Same as in A but narrow-spiking neurons
(putative interneurons).
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preferred condition, but their activity increased from 7.3 ± 2.2 to 13.7 ± 4.7
spikes/sec (p<0.05; paired t-test) for the neurons’ nonpreferred condition.

3.3.7 Timecourse of performance selectivity
To investigate the timecourse of the ketamine effect on LPFC activity, we
computed mean normalized selectivity indices (see Methods) for consecutive 10
min time bins for the ketamine and saline injection sessions (Figure 3.9).
Performance

selectivity

decreased

in

the

10

min

following

ketamine

administration and reached its minimum 10-30 min following the injection.
Although performance selectivity slowly increased afterwards, it did not return to
its pre-injection level during our recording sessions. For saline injections, there
were some fluctuations in performance selectivity, but the levels never fell below
those after ketamine injections and performance selectivity was similar at the end
and beginning of the recording sessions.

3.3.8 Intertrial neural activity
In 24.8% (85/343) of the neurons recorded during the ketamine sessions,
the intertrial activity was significantly different depending on whether the previous
trial was correct or a response error (p<0.05, t-test). The majority of the neurons
(83.5%) were more active following a response error on the previous trial than a
correct response. Ketamine decreased the activity for the neurons’ preferred trial
outcome from 8.42 ± 0.69 spikes/s to 7.26 ± 0.74 spikes/s (p<0.02; paired t-test).
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Figure 3.9: Time course of performance selectivity of LPFC neurons. Thick lines and thin lines
indicate the mean ± standard error of the mean selectivity on ketamine sessions and saline
sessions, respectively. The time of injection is indicated by a vertical dashed line.
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For the nonpreferred outcome, the activity increased from 4.77 ± 0.5 to 5.87
spikes/s (p<0.0001; paired t-test) following ketamine administration (Figure
3.10A).

A similar proportion of neurons exhibited differences in intertrial activity
between previous correct and error trials in the saline sessions (28% or 28/99
neurons). Like in the ketamine sessions, more neurons were active for errors
than correct response (64.3%, 18/28). The activity for the preferred condition did
not differ before and after saline injection (10.29 ± 1.28 versus 9.73 ± 1.39
spikes/s, respectively; p=0.28, paired t-test), but the activity for the nonpreferred
condition increased in the period after the injection (6.24 ± 0.9 versus 7.28.12
spikes/s, respectively; p<0.05, paired t-test) (Figure 3.10C).

3.3.8(i) Discriminability
There was a significant decrease in the ROC for the population from 0.74
± 0.01 to 0.58 ± 0.01 (p=8.1 * 10 -17) after the administration of ketamine (Figure
3.10B). Although there was also a decrease in ROC value from 0.72 ± 0.01 to
0.63 ±

0.02 (p<0.001) following the injection of saline (Figure 3.10D), the

reduction in discriminability was significantly larger for ketamine compared with
saline injections (-0.16 ± 0.02 versus -0.09 ± 0.02; p<0.02, paired t-test) (Figure
10E). This finding shows that ketamine decreased the discriminability during the
intertrial period between previous correct and erroneous response trials.
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Figure 3.10: Activity of LPFC neurons that showed performance-selectivity during the intertrial
period. A, Mean ± within-subject standard error of the mean spike density of the population for
preferred (red) and nonpreferred responses (blue) before (dashed lines) and after ketamine (solid
lines). B, ROC-values individual neurons are plotted before ketamine (abscissa) against ROCvalues after ketamine (ordinate). Circles and squares indicate neurons that were recorded from
monkey O and monkey T, respectively. A and B, Same as in A and B but for saline injections. E,
Distribution of changes in ROC-values for individual neurons after ketamine (black bars) and
saline (white bars) injections.
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3.3.8(ii) Reliability
The fano factor did not differ between before and after ketamine injections
for the preferred (2.21 ± 0.20 versus 2.63 ± 0.26; p=0.07, paired t-test) or
nonpreferred condition (1.94 ± 0.15 versus 2.11 ±.0.17; p=0.12, paired t-test)
during the intertrial period. The findings were similar for the saline injections for
the preferred (2.29 ± 0.50 versus 1.65 ± 0.5 p=0.09, paired t-test) and
nonpreferred condition (1.98 ± 0.37 versus 1.98 ±.0.3; p=0.93; paired t-test). This
finding indicates that ketamine did not affect the reliability of neural responses
during the intertrial period.

3.4 Discussion
Our data demonstrate that disruption of NMDARs impairs error-processing
in nonhuman primates: a single systemic subanesthetic dose of ketamine
reduced the differences in post-response activity between correct and error trials
of LPFC neurons in an antisaccade task. For those neurons that had higher
activity following an error than a correct response, ketamine increased the postresponse activity on correct trials only. Ketamine had no effect on the activity
following response errors in these neurons. Similarly, neurons that exhibited
higher post-response activity for correct trials, increased their activity following
ketamine on error trials but not on correct trials. The effect of these performancedependent increases in neural activity was that performance selectivity was
significantly reduced in LPFC neurons following ketamine administration.
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Consistent with the finding that ketamine impaired performance-related activity of
LPFC neurons, we also found that animals fixated longer on the stimulus on error
trials following ketamine, thereby resembling the fixation durations after correct
prosaccades. The absence of any behavioural or neural effects after saline
injections demonstrate that the effects were due to the action of ketamine and not
related to a decrease in task performance and performance-selectivity of LPFC in
response to the injection process.

Consistent with previous reports (Condy et al., 2005; Skoblenick and
Everling, 2012), we found that ketamine impaired the overall performance of
antisaccades and to a smaller degree also of prosaccades. We have previously
argued that this decline in performance might be related to impairments in the
animal’s ability to selectively maintain, or apply the appropriate task set
(Skoblenick and Everling, 2012). Such an impairment in context processing, i.e.
the ability to produce a different response to the same stimulus depending on the
goal or rule (Cohen and Servan-Schreiber, 1992; Miller and Cohen, 2001), has
also recently been described for the Dot Pattern Expectancy Task after ketamine
injections (Blackman et al., 2013). Here we found some evidence that ketamine
also affected the monkeys’ behaviour after a saccade. While ketamine did not
affect the behaviour after a correct response, both animals maintained much
longer fixation on the stimulus after a response error following ketamine
administration. In fact, fixation durations after a response error on an antisaccade
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trial resembled the fixation duration after a correct prosaccade. After both types
of responses, monkeys fixated the peripheral cue, but they were only rewarded
on the correct prosaccade trials. The finding that ketamine did not affect the
behaviour after correct antisaccades indicates that the delivery of the reward was
sufficient to signal that the trial was performed correctly even under ketamine and
that ketamine did not lead to a general increase in fixation durations after a
saccade. Instead, the data suggest that ketamine impaired the animal’s ability to
detect that their saccade was a response error, which would be consistent with
its effects on performance-related activity of LPFC neurons. This would also
explain the finding that post-error slowing after an antisaccade response error
disappeared after ketamine administration since post-error slowing has only been
found after aware but not unaware antisaccade errors in human subjects (Klein et
al., 2007).

In addition to its effect on action monitoring activity of LPFC neurons,
ketamine also altered neural activity during the intertrial period. Consistent with
the conflict-monitoring model (Botvinick et al., 2001; Miller and Cohen, 2001;
Yeung et al., 2004; Carter and van Veen, 2007), we found that a large proportion
of LPFC exhibited differences between correct and error trials in the following
intertrial period. This finding is reminiscent to the observation that some LPFC
neurons maintain conflict-related signal throughout the intertrial period (Mansouri
et al., 2007).

Ketamine reduced the differences between previous correct and
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previous error trials by decreasing the activity for the neurons’ preferred condition
and increasing the activity for their nonpreferred condition.

Although ketamine binds to other receptors besides the NMDAR, there is
strong evidence that its behavioural effects are mediated primarily by NMDAR
(Byrd et al., 1987; Ginski and Witkin, 1994; Duncan et al., 1999). Our data show
that ketamine increased the activity of LPFC neurons. This findings seems
surprising given that non-competitive NMDAR antagonists block the NMDA
channel (Huettner and Bean, 1988) and decrease the firing rate of neurons in
anesthetized animals (Moghaddam et al., 1997). However, increased LPFC
activity following a subanaesthetic dose of noncompetitive NMDAR antagonists
has also been found in rodent LPFC neurons (Jackson et al., 2004). The authors
hypothesized that the blockage of the NMDAR may lead to a compensatory
overactivation of AMPA receptors. Alternatively, ketamine has been shown to
block NMDAR in fast-spiking inhibitory interneurons more effectively than in
pyramidal neurons in rodents (Olney et al., 1999; Homayoun and Moghaddam,
2007; Seamans, 2008). We have recently also found increases in LPFC activity
following ketamine administration in nonhuman primates, but these effects were
similar for putative interneurons and pyramidal neurons (Skoblenick and Everling,
2012). Here we also found that ketamine had similar effects on putative
interneurons and pyramidal neurons. It is critical to note that we did not observe
an overall increase in performance-related LPFC activity here, but a selective
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increase in a neuron’s post-response activity for its nonpreferred performance.
The finding that some LPFC neurons were active after response errors and other
neurons that were more active after correct responses supports the notion that
opponent coding is a general feature of prefrontal decision making (Kusunoki et
al., 2010; Lennert and Martinez-Trujillo, 2013). We also show here that these two
response patterns are likely not mediated by different classes of neurons as
putative interneurons and pyramidal neurons were found in both populations.
This result is reminiscent to the absence of waveform differences between
ipsilateral and contralateral LPFC neurons (Lennert and Martinez-Trujillo, 2013).

Although we have found that ketamine altered action monitoring-activity of
LPFC neurons, we cannot assume that ketamine acted specifically on these
neurons. Resting-state functional MRI studies have demonstrated that ketamine
leads to an increase in global connectivity throughout the brain (Driesen et al.,
2013) and alters the relationship between task-positive and task-negative neural
systems (Anticevic et al., 2012), indicating that it does not selectively act on the
LPFC. Further, single neuron recordings in monkeys (Parent and Hazrati, 1995;
Phillips and Everling, 2012) combined with functional imaging studies and lesion
studies in humans suggest that a cortico-basal ganglia-thalamic circuit is involved
in action monitoring. In particular the ACC and LPFC are closely interconnected
(Bates and Goldman-Rakic, 1993; Paus, 2001) and it is possibly that the effects
were mediated by projections from the ACC to the LPFC. Note, however, that in
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humans with LPFC damage, the correct-trial ERN activity is equal to the errortrial ERN (Gehring and Knight, 2000), which clearly demonstrates that the LPFC
interacts with the anterior cingulate cortex in performance monitoring.

According to an influential model of error processing and reinforcement
learning (Holroyd and Coles, 2002), dopaminergic neurons in the ventral
tegmental area and the substantia nigra pars compacta send a negative
reinforcement signal to the anterior cingulate cortex. Support for this model has
come from subjects suffering from Parkinson’s disease, which is characterized by
a severe degeneration of dopaminergic neurons in the substantia nigra pars
compacta. It has been shown that individuals with Parkinson’s disease exhibit a
reduced ERN and deficits in performance monitoring (Jocham and Ullsperger,
2009). However, it has been argued by others that the mesoprefrontal dopamine
signal lacks the temporal precision required to generate the fast ERN (Jocham
and Ullsperger, 2009). In addition, more recent studies have also pointed towards
a role for serotonin, norepinephrine, GABA, and adenosine in performance
monitoring (Jocham and Ullsperger, 2009). NMDAR signalling interacts with all of
these systems, so it might be impossible to trace the effects of ketamine on
prefrontal
mechanism.

action-monitoring

activity

to

a

single

neuropharmacological
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Our results demonstrate that a low dose of ketamine alters actionmonitoring activity of LPFC neurons in nonhuman primates. These changes in
neural activity could explain the deficits in action-monitoring found in humans
after ketamine administration (Stone et al., 2011). Taken together, the findings
also support the hypothesis that an NMDAR dysfunction may mediate selfmonitoring deficits and ultimately leads to the psychotic symptoms in
schizophrenia (Bickel and Javitt, 2009).
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Chapter 4

Decreased outcome-sensitive beta-band activity
accompany gamma-band changes in the
monkey prefrontal cortex following ketamine
administration
A version of Chapter 4 will be submitted for publication as KJ Skoblenick, T
Womelsdorf, and S Everling, Decreased outcome-sensitive beta-band activity
accompany gamma-band changes in the monkey prefrontal cortex following
ketamine administration. To Biological Psychiatry.

4.1 Introduction
Schizophrenia is a debilitating mental illness affecting nearly 1% of the
world’s population and causes significant strain on many nations’ healthcare
systems (Knapp et al., 2004). The disease manifests itself in varying degrees of
three symptomatic categories. Positive symptoms which include hallucinations
and delusions, negative symptoms such as social withdrawal and anhedonia,
and cognitive symptoms including declining executive function and action
planning (Insel, 2010).

Older, preclinical animal models of schizophrenia focused on the
dopamine theory of schizophrenia (Seeman and Lee, 1975; Seeman, 1987;
Cohen and Servan-Schreiber, 1992) and produced animals with a clear positive
symptom phenotype. More recent theories that incorporate the role of aberrant
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glutamatergic signaling have led to the ketamine model of schizophrenia, which
generates animals that express behaviours analogous to all three symptomatic
categories (Javitt and Zukin, 1991; Olney and Farber, 1995; Olney et al., 1999).
Additionally, this model is able to induce a transient schizophrenia-like
behavioural phenotype in normal human subjects (Krystal et al., 1994; Adler et
al., 1999).

The assortment of symptoms experienced by a patient with schizophrenia
has implicated many brain regions and networks as potentially contributing to the
disease state. It is possible that a disconnect in communication between these
regions underlies all of the individual regional deficits (Friston, 1998; Phillips and
Silverstein, 2003). Inter-regional communication is facilitated by neural
oscillations (Salinas and Sejnowski, 2000, 2001; Tiesinga and Sejnowski, 2004),
with two distinct frequency ranges being of particular interest in schizophrenia.
Both beta-band activity (15-30Hz) and gamma-band activity (30+ Hz) have been
shown to be altered in both schizophrenia patients and animal models of the
disease (Uhlhaas and Singer, 2010). Non-human primates challenged with
ketamine exhibited similarities to schizophrenic patients in their sensory
processing event-related potentials (ERPs) (Gil-da-Costa et al., 2013) and their
performance in the anti-saccade task (Condy et al., 2005; Skoblenick and
Everling, 2012, 2014). Rodents tested with the ketamine model of schizophrenia
have consistently shown increased gamma-band activity (Pinault, 2008; Hakami

144
et al., 2009). Although beta-band activity has not been studied as thoroughly as
gamma-band oscillations, electroencephalograph (EEG) recordings have also
shown decreased beta-band activity in human schizophrenic patients (Krishnan
et al., 2005; Uhlhaas et al., 2006; Hirano et al., 2008).

One consistent finding in EEG recordings of the PFC in patients with
schizophrenia is a change in the error related negativity (ERN) (Kopp and Rist,
1999). Normally, this phenomenon appears as a brief negative deflection of the
event related potential immediately following an erroneous response to a cue.
The ERN is reliable and reproducible in the healthy human and non-human
primate population and can be measured even when the subject is unaware that
a mistake was performed (Falkenstein et al., 2000; Godlove et al., 2011; Murphy
et al., 2012; Phillips and Everling, 2014). It has been hypothesized that this
contributes to the performance monitoring network of the PFC and helps the
subject disengage from erroneous behaviours so that they may find a correct
behavioural response instead (Walsh and Anderson, 2012). In patients with
schizophrenia, the ERN amplitude is reduced (Bates et al., 2002). It is possible
that this decrease in ERN represents a failure of the PFC to recognize the
patient’s mistakes and consequently cannot engage the neuronal mechanisms
required to switch their behavioural set (Polli et al., 2008).
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This study aimed to examine the oscillatory properties of the primate
prefrontal cortex through intracranial recordings during a cognitively demanding
task and search for changes to this oscillatory activity induced by an acute
administration of the NMDA-antagonist, ketamine.

4.2 Materials and Methods
4.2.1 Animals
The experiments were performed in accordance with the Canadian
Council of Animal Care policy on the use of laboratory animals and all
procedures were approved by the Animal Use Subcommittee of the University
Western Ontario Council on Animal Care. For this study two male rhesus
monkeys (Macaca mulatta) weighing 5kg (Monkey T) and 7kg (Monkey O)
performed the behavioural tasks. The animals were implanted with a recording
chamber located above their lateral PFC and a plastic head restraint, as
previously described (Johnston and Everling, 2006). Post-surgical treatments
included analgesics, prophylactic antibiotics, and oversight by the university
veterinarian. Following surgical recovery, animals had cranial MR imaging to
obtain anatomical localization of the recording chambers (Figure 4.1).

4.2.2 Behavioural Task
Both animals were trained to perform the anti-saccade task in order to
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Figure 4.1: Anatomical MR images of electrode recording locations in both animals. Monkey O
had bilateral recording chamber implantation and had two sessions recorded from the right
hemisphere and three sessions recorded from the left hemisphere. Monkey T had all three
sessions recorded from his unilateral left hemisphere chamber. The red circle indicates the area
that the multi-electrode grid covered. P:Posterior; A: Anterior; L: Lateral; M: Medial.
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receive a liquid reward, as described previously by our laboratory (Skoblenick
and Everling, 2012). Briefly, the animal was enclosed in a light and sound
attenuated chamber with their head fixed and oriented towards a computer
monitor displaying the task. Each trial began with a fixation stimulus which was
replaced with a rule cue after fixation for 100ms. Monkey O was trained that a
green coloured rule cue indicated a pro-saccade task and a red-coloured cue
indicated an anti-saccade task. The colour rules were reversed for training
Monkey T. After a 1000-1200ms instruction period, a white, circular, peripheral
stimuli appeared either 8° to the left or right of the central fixation cue. Prosaccade trials required the animal look at this stimuli, while anti-saccade trials
required the animal to look towards a blank location on the screen diametrically
opposite to the stimuli’s position. Following correct trials, a liquid reward was
delivered to the monkey’s mouth through a sipping tube immediate after a
saccade to the correct target location. Eye gazes in any direction other than
towards or away from the stimuli ended the trial immediately. Following the
completion of a trial the screen was blanked and a new trial began after a 200ms
inter trial interval. Trials were presented in a randomized order such that each
task variant occurred equally. The animal’s eye position was recorded and
digitized at either 120Hz using an ISCAN infrared pupillary tracking system for
Monkey O (ISCAN, Woburn MA) or at 1000Hz using an Eyelink 1000 infrared
pupillary tracking system for both Monkey O and Monkey T (SR Research,
Mississauga ON).
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4.2.3 Electrode Recording
The setup for multi-electrode recording sessions began a day before the
experimental session with the installation of the semi-chronic multi-electrode grid
(Neuronitek, London ON) into the recording chamber. The 36 tungsten electrodes
(FHC, Bowdoin ME) were lowered through a silicone membrane and into the
monkey’s lateral PFC, providing 32 recording channels and 4 reference
channels. Each electrode was lowered manually using a micro-screwdriver until
background activity was observed on a maximal number of recording channels.
The animal was returned to its cage until the next day so that the electrodes had
time to settle in the cortical tissue. On an experimental session day, the animal
was returned to the sound-attenuated chamber and the electrode grid was
connected to a head stage and amplifying unit. Neuronal spiking activity and LFP
activity from each channel were combined with performance and eye-tracking
data in a multi acquisition processor system (Plexon, Dallas TX) and sorted
offline using 2D and 3D principal component analysis. Subsequent recording
days only required reconnecting the head stage and a minimal adjustment to
each electrode’s depth before spiking neuronal activity was observed. The multi
electrode grid was left implanted for two weeks, after which it was removed for
cleaning and sterilization of the recording chamber.

4.2.4 Drug Administration
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Each session began with a 15 minute pre-injection period, during which
the animal performed 200-250 trials with accompanying PFC recordings. The
animals both averaged less than 15% error rate on both pro- and anti-saccade
trials. At the 15 minute mark, the experimental paradigm was paused briefly and
the animal was given a 0.4mg/kg intramuscular injection of ketamine diluted in
saline to 0.4ml into their right triceps brachii muscle. The experiment booth was
closed and the experimental task resumed. In total, the injection process
introduced less than a 20s pause and the animal began performing the task
again immediately. Both animals had their dose titrated between 0.2mg/kg and
1.0mg/kg to optimize a dose that elicited a behavioural deficit but had no
appreciable anesthetic effect (Condy et al., 2005). The animals’ behaviour
continued at baseline performance levels for approximately 5 minutes before the
behavioural effects of the ketamine injection became apparent. Sessions would
then continue for another 45 minutes to monitor the effects of ketamine. Control
experiments with injections of saline did not produce any significant changes
between pre- and post-injection periods in the animals’ behavioural performance
or neuronal activity. Experiment sessions with ketamine were spaced at least 3
days apart to ensure there were no cumulative effect of the drug or changes to
the pre-injection baseline activity.

4.2.5 Data Analysis
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Electrophysiological data was analyzed using custom scripts for Matlab
(Mathworks) that made use of the FieldTrip toolbox developed by the Donders
Institute for Brain, Cognition and Behaviour. For LFP analysis, the continuous
analog signal was divided into discrete trials using event time markers provided
by the Plexon recording system. Data was filtered with a low-pass filter at 150Hz
and line noise was removed at 60Hz and 120Hz using a discrete Fourier
transform. Z-score thresholding, and component analysis were used to detect
and discard any additional mechanical artifacts in the analog signal. In order to
remove the reward artifact, the data was first downsampled to 1/100th the polling
rate after which component analysis was run to manually identify those
components that contained the artifacts. The component analysis was then
reperformed on the original data without downsampling to remove the artifact
components from the final data set. To determine time-locked LFP power,
frequency analysis was performed using the multitaper method with a discrete
prolate spheroidal sequence taper set around a 0.667s window every 50ms for
the low frequency range (1-50Hz) and a 0.33s window every 50ms for the high
frequency range (45-150Hz). The LFP data for each trial was normalized to the
oscillatory activity on the same channel during the preceding intertrial interval
(500ms preceding fixation onset) resulting in a Z-score that could be compared
between channels, sessions, and animals. Statistical analysis on the resulting
time-frequency-LFP Power maps used a nonparametric cluster-based analysis
that created a T-value map for the significance level between two conditions and
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highlighted time-frequency epochs with statistical significance (Maris and
Oostenveld, 2007). Neuronal spiking activity was analyzed as previously
described (Skoblenick and Everling, 2012).

4.3 Results
Data was collected from 8 testing sessions (5 with Monkey O and 3 with
Monkey T) yielding 158 LFP channels and 215 neurons for analysis. Channels
without usable signals were removed from the analysis. Behavioural effects were
similar to those previously described (Skoblenick and Everling, 2012, 2014) and
are summarized in Table 4.1.

4.3.1 Prefrontal cortex exhibits outcome-dependent beta-band LFP activity
To examine how the beta-band range of LFP activity may be involved in a
task requiring explicit cognitive control, we recorded the LFP signal in 2 monkeys.
After lower frequency analysis was performed (1-50 Hz), a clear time and
frequency locked epoch emerged following the animal’s saccade response to the
trial stimulus. The response occurred most strongly between 15-30 Hz which
corresponds to beta-band oscillations. Further, this response appeared to be
outcome specific, showing a stronger effect following trials in which the animal
made a correct response (Figure 4.2). After the effect was visualized the
statistical strength of these findings were challenged with a cluster-based
analysis. The resulting T-score map highlighted a cluster between 0.3s to 0.75s
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after saccade onset that showed a significant difference in the LFP activation
between correct and error trials. To better illustrate the evolution of this
difference, the mean LFP power of the relevant oscillatory range (15-30 Hz) was
plotted as mean +/- SEM over the course of the trial (Figure 4.2B).
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Table 4.1: Effect of ketamine on performance measurements in the anti-saccade task. SRT:
Saccade response time; Error Rate: percentage of trials when a pro-saccade was performed
instead of an anti-saccade or vice-versa; Return Time Δ: Difference in time after saccade
completion that that animal remained focused on their target location (Error – Correct).
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Figure 4.2: Performance-selective differences in beta-band LFP power. A heatmap displaying the
trial time from saccade onset (x-axis) and frequencies (y-axis) shows the difference between the
mean activity following a correct trial versus an error trial (Panel A). The colour bar indicates the zscore value obtained from (correct trials – error trials) baseline normalized z-score. Positive values
indicate stronger activity during correct trials while negative values show time-frequency points
with stronger activity for error trials. The black outline indicates the region in which statistical
significance was found via cluster-based analysis. Panel B shows the mean Z-score +/- SEM for
the beta-band frequency range (15-30Hz) aligned on saccade onset for correct (blue) and error
(red) trials.
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4.3.2 Ketamine reduces performance selectivity of beta-band LFP activity
After observing the selectivity in the beta-band response following task
completion we next analyzed how these changes were affected by the
administration of a subanesthetic dose of ketamine. In previous studies we have
described the effect of this drug on response time and error rates (Skoblenick
and Everling, 2012, 2014). The findings were once again similar in this study. In
regards to beta-band activity however, a large decrease in performance
selectivity was observed (Figure 4.3A). The overall beta-band activity was
decreased (pre-ketamine mean Z-score: 0.132 ± 0.267, post-ketamine mean Zscore: -0.278 ± 0.205, p<0.001) to the detriment of the correct-selective epoch
beginning 200ms after saccade onset. The differences in (correct – error) LFP
power were compared for statistical significance and the cluster-based analysis
once again found a time-frequency epoch significantly different between pre- and
post-ketamine conditions. The evolution of this change in selective over the
course of the trial was also plotted as mean power (15-30Hz) +/- SEM to illustrate
how pre- and post-ketamine conditions differed (Figure 4.3B).

4.3.3 No Significant Gamma-Band Selectivity
With

the

gamma-band

of

oscillatory

activity

also

implicated

in

schizophrenia, we next examined how the higher frequencies responded to the
task before and after ketamine administration. Initial difference maps were
generated between (correct – error) task outcomes and a clearly defined error-
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Figure 4.3: Difference in performance selectivity following ketamine administration. The heatmap
in Panel A displays the trial time from saccade onset (x-axis) and frequencies (y-axis) with the
colour bar indicating the difference in absolute selectivity calculated as (absolute difference
between correct and error trials after ketamine) – (absolute difference between correct and error
trials before ketamine). Thus a positive value indicates a time-frequency area in which the
difference between correct and error trials was greater after ketamine injection, whereas a
negative value indicates the performance selectivity was greater before ketamine. The epoch
found to be statistically significant through cluster-based analyses is outlined in black. In Panel B
the mean difference between correct and error trials +/- SEM in the beta-band range (15-30Hz) is
plotted for both pre-ketamine values (blue) and post-ketamine values (red).
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selectivity before ketamine was visible, however clustered-based comparisons
between the correct and error heatmaps did not reach significance values in any
relevant areas (Figure 4.4). Overall mean gamma power (40-120Hz) during the
trial was significant increased following ketamine administration (pre-ketamine
mean Z-score = -0.1584 +/- 0.3521 post-ketamine mean Z-score = 0.8535 +/0.5539, p<0.000001 Student t-test).

4.3.4 Gamma-Band Activity Follows Neural Spiking Patterns
Lastly, similarities were observed between the gamma-band LFP patterns
and neural spiking activity changes following ketamine administration. By
comparing the mean LFP powers in the high gamma range (60-120Hz) across
the duration of a trial to the mean spiking power, we found correlations between
these two measurements (Figure 4.5). Indeed, pre-ketamine high-gamma LFP
powers follow a very similar pattern of evolution and peak-time to the average
spiking activity of neurons in the PFC. Further validation of these parallels can be
observed post-ketamine. The pre-ketamine LFP power was found to be
significantly correlated with the mean neuronal spiking rate in both correct
(r=0.58, p<0.001) and error (r=0.84, p<0.0001) trials as well as post-ketamine in
correct (r=0.37, p<0.05) and error (r=0.87, p<0.0001) trials.
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Figure 4.4: Outcome specific heat maps for gamma-band frequencies. The mean difference
between correct and error trials for pre-ketamine trials (Panel A) and post-ketamine trials (Panel
B) are displayed, with positive values indicating stronger activity for correct trials and negative
values showing stronger activity for error trials. No significance was found through the cluster
based analyses for the pre-ketamine selectivity map, however overall gamma-band activity was
significant increased between pre-ketamine and post-ketamine values.

159

Figure 4.5: Gamma-band LFP power and corresponding neuronal firing rates. The mean high
gamma-band (60-120Hz) activity +/- SEM is plotted in Panel A contrasting both pre-ketamine
(solid lines) correct trials (blue) and error trials (red) with post ketamine (dashed lines) values. The
pattern of activity is notably similar to the mean spiking activity simultaneously measured from
neurons in the PFC (Panel B) in both their peak activity epoch and their response to ketamine
administration.
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4.4 Discussion
This experiment set out to determine if the LFP events observed during
other tasks that challenge a subject’s cognitive control over behaviour may also
be measured in relevant epochs of the anti-saccade task. Further, we wanted to
test if these events are altered by ketamine in a manner similar to the aberrant
oscillatory activity found in human patients with schizophrenia (Uhlhaas and
Singer, 2010, 2013). Our strongest findings were in the beta-band frequency
range (15-30Hz) and were sensitive to the outcome of the trial. The PFC in
conjunction with the anterior cingulate cortex have been shown to have an
important role in performance monitoring during tasks requiring the cognitive
suppression of automatic responses (MacDonald et al., 2000; Swick and Turken,
2002; Ridderinkhof et al., 2004; Walton et al., 2004). Our data show that the
beta-band may be involved in this feedback monitoring, as the timing occurs only
after the animal’s response has been made and is dependent on whether or not
the trial was performed correctly.

Alternatively, the beta-band range of oscillations has been demonstrated
in other brain regions to have a very strong impact on motor control
(Androulidakis et al., 2006; Swann et al., 2009). Increased beta activity
decreases the ability of a subject to initiate a new movement or to disengage
from a current action (Gilbertson et al., 2005; Pogosyan et al., 2009). It has also
been shown in human EEG studies to increase in tasks during which a muscle
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must maintain a specific action against an unpredictable amount of force
(Androulidakis et al., 2007). Thus the beta activity we observe in the PFC may be
an efferent signal to the saccade system to hold the eye’s position at the correct
location. This maintenance at a correct location has been hypothesized to allow
the organism to gain more information and increase attention to a desirable
outcome or to process the stimuli that resulted in a reward (Engel and Fries,
2010). Incorrect trials, with their decreased beta-band activity, allow for a quicker
disengagement from the peripheral stimulus because of its unrewarding
properties.

The introduction of ketamine to this pathway appears to disrupt the
outcome specific signal causing the animals to no longer display beta-band
activity that is selective for correct trials. The beta signal is elicited in the same
epoch for both correct and error trials, indicating that the animal either does not
recognize the trial was erroneous or that the PFC is no longer able to send
outcome specific efferents to downstream locations. These results corroborate
our previous findings with regards to a change in the animal’s post-response
reaction time (Skoblenick and Everling, 2014). In those studies we discovered
that pre-ketamine, the animal’s gaze would remain fixed on the target location
longer after making a correct pro- or anti-saccade when compared to error trials.
After ketamine, the animal’s gaze lingered much longer on the stimulus for an
incorrect anti-saccade trial, similar to their post-response reaction after making a
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correct pro-saccade (Table 4.1). Our beta-band findings showed that after
ketamine, the beta-band response was similar for both correct and error trials.
This supports the hypothesis that beta-band activity can maintain a current motor
state, in this case a saccade target location. Evidence for this beta-band
influence on behavior has also been demonstrated in hypodopaminergic states
as Parkinsons disease (Limousin et al., 1995; Brown, 2003). It is suspect that the
increased beta-band activity observed in Parkinsons patients may contribute to
the decreased ability to initiate motor movements based on internal or cognitive
cues (Kuhn et al., 2004; Chen et al., 2007; Kuhn et al., 2008). Taken together,
these results show that the similarities in beta-band activity after ketamine
administration (Figure 4.2B) may act as a physiological basis for the similarities
between correct and error trial post saccade response times (Table 4.1). This
epoch specific increase in beta-band activity may also correspond with taskspecific prefrontal hypodopaminergic states observed in schizophrenia (Dworkin
and Opler, 1992; Abi-Dargham and Moore, 2003; Stone et al., 2007).
Additionally, we found that the generalized beta power was decreased, which
corresponds both with the increased PFC dopamine release caused by ketamine
(Lorrain et al., 2003) and the resting-state beta power decrease in schizophrenia
(Krishnan et al., 2005; Uhlhaas et al., 2006). Combining these findings reinforces
the critical interplay between the glutamatergic and dopaminergic systems in
schizophrenia and its associated animal models.
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Gamma-band oscillations have been studied extensively in schizophrenia
for many years as well but have been debated whether they are increased or
decreased in the disease (Kocsis et al., 2013). NMDA antagonism in humans
(Hong et al., 2010) and animal models of schizophrenia (Pinault, 2008; Kocsis,
2012) have demonstrated an increase in gamma-band activity whereas human
studies had been showing a decrease in gamma-band signal (Gandal et al.,
2012). Recently, studies that have revisited human schizophrenia data found two
two trends that may explain these discrepancies. Firstly, there appears to be an
overall increase in gamma activity resulting in more background noise and thus a
relatively decreased signal (Kikuchi et al., 2011; Spencer, 2011; Suazo et al.,
2014) and secondly, that antipsychotic medications decrease the gamma-band
activity (Jones et al., 2012).

Our study found that there was indeed an overall increase in gamma-band
activity. This increase mirrored the increase in spiking activity that we had
previously described (Skoblenick and Everling, 2012). The increased spiking
activity was found to be reducing the signal to noise ratio of task specific neurons
in the prefrontal cortex because of their increased activity due to ketamine
administration. It may be that the increase in gamma-band activity we are
observing in the primate PFC may be another manifestation of this increase in
background noise and a loss in an additional dimension of information
conveyance. Further, these similarities lend credence to the idea that oscillatory
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activity in this high gamma range may be reflective of the net spiking activity of
nearby neurons in the macaque brain (Ray et al., 2008; Whittingstall and
Logothetis, 2009). Additional investigation is required to support this idea but this
opens the possibility to measure gamma-band power as a proxy measurement
for spiking activity.

In summary, beta-band activity appears to play an important role in the
PFC for determining how to respond to correct and erroneous trial outcomes.
This performance-sensitive frequency and time-locked pattern is vulnerable to
disruption in the ketamine model of schizophrenia. The NMDA antagonist
removes any differentiation between correct and error trials following saccade
response. In addition, ketamine also increased the overall activity in the gammaband range, potentially reflecting decreased cognitive control in the PFC and
similar increases in background noise as observed in the neuronal spiking
activity. These results further validate the neural similarities between humans
with schizophrenia and the ketamine model of schizophrenia in non-human
primates.

165
4.5 References
Abi-Dargham A, Moore H (2003) Prefrontal DA transmission at D1 receptors and
the pathology of schizophrenia. Neuroscientist 9:404-416.
Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999)
Comparison of ketamine-induced thought disorder in healthy volunteers
and thought disorder in schizophrenia. Am J Psychiatry 156:1646-1649.
Androulidakis AG, Doyle LM, Gilbertson TP, Brown P (2006) Corrective
movements in response to displacements in visual feedback are more
effective during periods of 13-35 Hz oscillatory synchrony in the human
corticospinal system. Eur J Neurosci 24:3299-3304.
Androulidakis AG, Doyle LM, Yarrow K, Litvak V, Gilbertson TP, Brown P (2007)
Anticipatory changes in beta synchrony in the human corticospinal system
and associated improvements in task performance. Eur J Neurosci
25:3758-3765.
Bates AT, Kiehl KA, Laurens KR, Liddle PF (2002) Error-related negativity and
correct response negativity in schizophrenia. Clin Neurophysiol 113:14541463.
Brown P (2003) Oscillatory nature of human basal ganglia activity: relationship to
the pathophysiology of Parkinson's disease. Mov Disord 18:357-363.
Chen CC, Litvak V, Gilbertson T, Kuhn A, Lu CS, Lee ST, Tsai CH, Tisch S,
Limousin P, Hariz M, Brown P (2007) Excessive synchronization of basal
ganglia neurons at 20 Hz slows movement in Parkinson's disease. Exp
Neurol 205:214-221.
Cohen JD, Servan-Schreiber D (1992) Context, cortex, and dopamine: a
connectionist approach to behavior and biology in schizophrenia. Psychol
Rev 99:45-77.
Condy C, Wattiez N, Rivaud-Pechoux S, Gaymard B (2005) Ketamine-induced
distractibility: An oculomotor study in monkeys. Biol Psychiatry 57:366372.
Dworkin RH, Opler LA (1992) Simple schizophrenia, negative symptoms, and
prefrontal hypodopaminergia. Am J Psychiatry 149:1284-1285.
Engel AK, Fries P (2010) Beta-band oscillations--signalling the status quo? Curr
Opin Neurobiol 20:156-165.
Falkenstein M, Hoormann J, Christ S, Hohnsbein J (2000) ERP components on
reaction errors and their functional significance: a tutorial. Biol Psychol
51:87-107.
Friston KJ (1998) The disconnection hypothesis. Schizophr Res 30:115-125.
Gandal MJ, Edgar JC, Klook K, Siegel SJ (2012) Gamma synchrony: towards a
translational biomarker for the treatment-resistant symptoms of
schizophrenia. Neuropharmacology 62:1504-1518.
Gil-da-Costa R, Stoner GR, Fung R, Albright TD (2013) Nonhuman primate
model of schizophrenia using a noninvasive EEG method. Proc Natl Acad
Sci U S A 110:15425-15430.

166
Gilbertson T, Lalo E, Doyle L, Di Lazzaro V, Cioni B, Brown P (2005) Existing
motor state is favored at the expense of new movement during 13-35 Hz
oscillatory synchrony in the human corticospinal system. J Neurosci
25:7771-7779.
Godlove DC, Emeric EE, Segovis CM, Young MS, Schall JD, Woodman GF
(2011) Event-related potentials elicited by errors during the stop-signal
task. I. Macaque monkeys. J Neurosci 31:15640-15649.
Hakami T, Jones NC, Tolmacheva EA, Gaudias J, Chaumont J, Salzberg M,
O'Brien TJ, Pinault D (2009) NMDA receptor hypofunction leads to
generalized and persistent aberrant gamma oscillations independent of
hyperlocomotion and the state of consciousness. PLoS One 4:e6755.
Hirano S, Hirano Y, Maekawa T, Obayashi C, Oribe N, Kuroki T, Kanba S,
Onitsuka T (2008) Abnormal neural oscillatory activity to speech sounds in
schizophrenia: a magnetoencephalography study. J Neurosci 28:48974903.
Hong LE, Summerfelt A, Buchanan RW, O'Donnell P, Thaker GK, Weiler MA,
Lahti AC (2010) Gamma and delta neural oscillations and association with
clinical
symptoms
under
subanesthetic
ketamine.
Neuropsychopharmacology 35:632-640.
Insel TR (2010) Rethinking schizophrenia. Nature 468:187-193.
Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of
schizophrenia. Am J Psychiatry 148:1301-1308.
Johnston K, Everling S (2006) Monkey dorsolateral prefrontal cortex sends taskselective signals directly to the superior colliculus. J Neurosci 26:1247112478.
Jones NC, Reddy M, Anderson P, Salzberg MR, O'Brien TJ, Pinault D (2012)
Acute administration of typical and atypical antipsychotics reduces EEG
gamma power, but only the preclinical compound LY379268 reduces the
ketamine-induced rise in gamma power. Int J Neuropsychopharmacol
15:657-668.
Kikuchi M, Hashimoto T, Nagasawa T, Hirosawa T, Minabe Y, Yoshimura M,
Strik W, Dierks T, Koenig T (2011) Frontal areas contribute to reduced
global coordination of resting-state gamma activities in drug-naive patients
with schizophrenia. Schizophr Res 130:187-194.
Knapp M, Mangalore R, Simon J (2004) The global costs of schizophrenia.
Schizophr Bull 30:279-293.
Kocsis B (2012) Differential role of NR2A and NR2B subunits in N-methyl-Daspartate receptor antagonist-induced aberrant cortical gamma
oscillations. Biol Psychiatry 71:987-995.
Kocsis B, Brown RE, McCarley RW, Hajos M (2013) Impact of ketamine on
neuronal network dynamics: translational modeling of schizophreniarelevant deficits. CNS Neurosci Ther 19:437-447.

167
Kopp B, Rist F (1999) An event-related brain potential substrate of disturbed
response monitoring in paranoid schizophrenic patients. J Abnorm
Psychol 108:337-346.
Krishnan GP, Vohs JL, Hetrick WP, Carroll CA, Shekhar A, Bockbrader MA,
O'Donnell BF (2005) Steady state visual evoked potential abnormalities in
schizophrenia. Clin Neurophysiol 116:614-624.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD,
Heninger GR, Bowers MB, Jr., Charney DS (1994) Subanesthetic effects
of the noncompetitive NMDA antagonist, ketamine, in humans.
Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Arch Gen Psychiatry 51:199-214.
Kuhn AA, Williams D, Kupsch A, Limousin P, Hariz M, Schneider GH, Yarrow K,
Brown P (2004) Event-related beta desynchronization in human
subthalamic nucleus correlates with motor performance. Brain 127:735746.
Kuhn AA, Kempf F, Brucke C, Gaynor Doyle L, Martinez-Torres I, Pogosyan A,
Trottenberg T, Kupsch A, Schneider GH, Hariz MI, Vandenberghe W,
Nuttin B, Brown P (2008) High-frequency stimulation of the subthalamic
nucleus suppresses oscillatory beta activity in patients with Parkinson's
disease in parallel with improvement in motor performance. J Neurosci
28:6165-6173.
Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret
JE, Benabid AL (1995) Effect of parkinsonian signs and symptoms of
bilateral subthalamic nucleus stimulation. Lancet 345:91-95.
Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003) Effects of
ketamine and N-methyl-D-aspartate on glutamate and dopamine release
in the rat prefrontal cortex: modulation by a group II selective metabotropic
glutamate receptor agonist LY379268. Neuroscience 117:697-706.
MacDonald AW, 3rd, Cohen JD, Stenger VA, Carter CS (2000) Dissociating the
role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive
control. Science 288:1835-1838.
Maris E, Oostenveld R (2007) Nonparametric statistical testing of EEG- and
MEG-data. J Neurosci Methods 164:177-190.
Murphy PR, Robertson IH, Allen D, Hester R, O'Connell RG (2012) An
electrophysiological signal that precisely tracks the emergence of error
awareness. Front Hum Neurosci 6:65.
Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia.
Arch Gen Psychiatry 52:998-1007.
Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model
of schizophrenia. J Psychiatr Res 33:523-533.
Phillips JM, Everling S (2014) Event-related potentials associated with
performance monitoring in non-human primates. Neuroimage 97C:308320.

168
Phillips WA, Silverstein SM (2003) Convergence of biological and psychological
perspectives on cognitive coordination in schizophrenia. Behav Brain Sci
26:65-82; discussion 82-137.
Pinault D (2008) N-methyl d-aspartate receptor antagonists ketamine and MK801 induce wake-related aberrant gamma oscillations in the rat neocortex.
Biol Psychiatry 63:730-735.
Pogosyan A, Gaynor LD, Eusebio A, Brown P (2009) Boosting cortical activity at
Beta-band frequencies slows movement in humans. Curr Biol 19:16371641.
Polli FE, Barton JJ, Thakkar KN, Greve DN, Goff DC, Rauch SL, Manoach DS
(2008) Reduced error-related activation in two anterior cingulate circuits is
related to impaired performance in schizophrenia. Brain 131:971-986.
Ray S, Crone NE, Niebur E, Franaszczuk PJ, Hsiao SS (2008) Neural correlates
of high-gamma oscillations (60-200 Hz) in macaque local field potentials
and their potential implications in electrocorticography. J Neurosci
28:11526-11536.
Ridderinkhof KR, Ullsperger M, Crone EA, Nieuwenhuis S (2004) The role of the
medial frontal cortex in cognitive control. Science 306:443-447.
Salinas E, Sejnowski TJ (2000) Impact of correlated synaptic input on output
firing rate and variability in simple neuronal models. J Neurosci 20:61936209.
Salinas E, Sejnowski TJ (2001) Correlated neuronal activity and the flow of
neural information. Nat Rev Neurosci 2:539-550.
Seeman P (1987) Dopamine receptors and the dopamine hypothesis of
schizophrenia. Synapse 1:133-152.
Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical
potency and presynaptic action on dopamine neurons. Science 188:12171219.
Skoblenick K, Everling S (2012) NMDA antagonist ketamine reduces task
selectivity in macaque dorsolateral prefrontal neurons and impairs
performance of randomly interleaved prosaccades and antisaccades. J
Neurosci 32:12018-12027.
Skoblenick K, Everling S (2014) N-methyl-d-aspartate Receptor Antagonist
Ketamine Impairs Action-monitoring Activity in the Prefrontal Cortex. J
Cogn Neurosci 26:577-592.
Spencer KM (2011) Baseline gamma power during auditory steady-state
stimulation in schizophrenia. Front Hum Neurosci 5:190.
Stone JM, Morrison PD, Pilowsky LS (2007) Glutamate and dopamine
dysregulation in schizophrenia--a synthesis and selective review. J
Psychopharmacol 21:440-452.
Suazo V, Diez A, Montes C, Molina V (2014) Structural correlates of cognitive
deficit and elevated gamma noise power in schizophrenia. Psychiatry Clin
Neurosci 68:206-215.

169
Swann N, Tandon N, Canolty R, Ellmore TM, McEvoy LK, Dreyer S, DiSano M,
Aron AR (2009) Intracranial EEG reveals a time- and frequency-specific
role for the right inferior frontal gyrus and primary motor cortex in stopping
initiated responses. J Neurosci 29:12675-12685.
Swick D, Turken AU (2002) Dissociation between conflict detection and error
monitoring in the human anterior cingulate cortex. Proc Natl Acad Sci U S
A 99:16354-16359.
Tiesinga PH, Sejnowski TJ (2004) Rapid temporal modulation of synchrony by
competition in cortical interneuron networks. Neural Comput 16:251-275.
Uhlhaas PJ, Singer W (2010) Abnormal neural oscillations and synchrony in
schizophrenia. Nat Rev Neurosci 11:100-113.
Uhlhaas PJ, Singer W (2013) High-frequency oscillations and the neurobiology of
schizophrenia. Dialogues Clin Neurosci 15:301-313.
Uhlhaas PJ, Linden DE, Singer W, Haenschel C, Lindner M, Maurer K, Rodriguez
E (2006) Dysfunctional long-range coordination of neural activity during
Gestalt perception in schizophrenia. J Neurosci 26:8168-8175.
Walsh MM, Anderson JR (2012) Learning from experience: event-related
potential correlates of reward processing, neural adaptation, and
behavioral choice. Neurosci Biobehav Rev 36:1870-1884.
Walton ME, Devlin JT, Rushworth MF (2004) Interactions between decision
making and performance monitoring within prefrontal cortex. Nat Neurosci
7:1259-1265.
Whittingstall K, Logothetis NK (2009) Frequency-band coupling in surface EEG
reflects spiking activity in monkey visual cortex. Neuron 64:281-289.

170

Chapter 5

Discussion
5.1 Summary of Findings
5.1.1 Ketamine increases error rates and reaction times in the anti-saccade task
Ketamine administration in healthy human subjects can induce a
schizophrenia-like phenotype as demonstrated in a number of different
behavioural experiments (Krystal et al., 1994; Malhotra et al., 1996). The antisaccade task is particularly useful in this situation because a relatively simple
training procedure yields a robust data set that describes a number of cognitive
functions (Everling and Fischer, 1998). Extensive studies have repeatedly
demonstrated that patients with schizophrenia show a significant impairment in
this task (Fukushima et al., 1988; Fukushima et al., 1990; Mazhari et al., 2011).
Although a single study showed a non-significant decrease in the ability for
normal human subjects to perform this task after being administered ketamine
(Radant et al., 1998), a non-human primate study showed a statistically
significant effect of ketamine (Condy et al., 2005). Prior to the ketamine injection,
monkeys exhibited error rates and reaction times similar to normal healthy
humans. After the ketamine injection had taken effect however, these values
regressed and instead resembled reaction times and error rates of human
patients with schizophrenia (Condy et al., 2005).
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The results across all three chapters and in all three monkeys that
performed the task corroborated these findings. We saw a baseline error rate of
approximately 20% in the anti-saccade task prior to ketamine, which transiently
increased to up to 80% error rate at the height of the ketamine effect. To build
upon these findings, we first looked in detail at the types of errors made by the
subjects.

Through the inclusion of trials with a rule-memorization component, I
identified a separate and significant effect that ketamine induced on the monkeys’
working memory. Error rates were increased in all anti-saccade tasks but those
trials that required the retrieval and maintenance of the rule from working
memory were affected to a greater degree. This significant separation between
the rule-visible and rule-memorized trials represents the negative effect ketamine
exerts specifically on working memory, similar to other reports on impaired
working memory in the ketamine model of schizophrenia (Taffe et al., 2002).
After finding a high error rate in rule-visible trials, it became evident that the
cognitive deficits being induced by ketamine are occurring at an early stage of
the neural pathways involved in this task. Even with rule information present in
the monkeys’ visual field, they were still unable to saccade away from the
stimulus in an anti-saccade trial. Possible explanations include either a total
inability to perform rule-identification or a lack of feedback indicating that a
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correct trial produces a more favourable outcome in the form of a reward. The
electrophysiological changes in the performance monitoring component of PFC
spiking activity strongly implicates the latter possibility. Similarly in the LFP
results, we saw changes in the beta band specifically at the post-response
epoch. The reduced selectivity of the beta band LFP power for correct trials over
error trials also reflects a decrease in the PFC sensitivity to rewarded versus
unrewarded outcome. Patients with schizophrenia may be experiencing a similar
deficit in outcome monitoring (Silver et al., 2006). When these patients fail to
recognize that an error has occurred there may be no signal to change their
behavior or recall the relevant rule, which would aid them in getting back to
correct trial outcomes. A correlate of this effect is also already observed in some
fashion as the decreased error related negativity and decreased feedback
negativity compared to normal subjects (Morris et al., 2008).

This impaired error response also gives a physiological basis for the
impaired learning associated with schizophrenia. Feedback-related negativity is
critical for learning (Walsh and Anderson, 2012) so a lifetime of reduced
feedback would accumulate a number of cognitive impairments over experiences
that would normally teach unimpaired individuals a wide range of behaviours.
Immediate feedback learning is also important for adapting to challenges that
evolve after the initial rules have been established, like the Wisconsin Card
Sorting Task. The decreased ability for schizophrenia patients to adapt to
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changes in the card sorting rules over time may be reflective of this impaired
performance monitoring feedback in the PFC (Everett et al., 2001; Ohrmann et
al., 2008).

The speed at which the monkeys made this erroneous action provided an
insight into the potential neuronal pathways responsible. Prior to ketamine
administration, the few errors being made by the subjects had very short
saccadic reaction times (SRTs). Reaction times lower than 100ms are classified
as express saccades (Boch et al., 1984) and at this speed of reaction time the
saccade is being triggered by a direct pathway from the visual input to the
saccade generating system in the superior colliculus (Freund et al., 1986; Dorris
et al., 1997; Sommer and Wurtz, 2001). This implies that the errors are
behaviourally distinct from those observed after ketamine administration. The
long SRTs found on error trials after ketamine indicate that these errors are no
longer associated with the triggering of the express saccade pathway. Instead, it
suggests that there may be a breakdown in the processes that the subject uses
to select the saccade target location. Automatic saccades caused by the express
saccade pathway become incorrectly selected saccade targets due to the
ketamine-induced deficits in cognition. This change in reaction times was
associated with changes in the activity of the PFC in human schizophrenia
patients as well (Bender et al., 2013).
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For the first time in non-human primates, we simultaneously recorded
single unit neuronal activity and local field potentials in the PFC while the animal
performed an anti-saccade task both before and after the administration of
ketamine. This allowed us to gain information from a region in brain often
implicated for the cognitive dysfunction observed in schizophrenia. Similar to
previous studies of neuronal activity in the PFC, we found neurons exhibiting
rule-selectivity, where the selective neuron would produce more spiking activity
for their preferred task - either pro- or anti-saccade (Everling and DeSouza, 2005;
Johnston and Everling, 2006, 2009). The changes in firing rate we observed in
the PFC directly correlated with the onset and offset of the behavioural changes
observed. Additionally, the changes observed in the local field potential at both
the beta and high gamma band ranges also aligned with the behavioural
deviations. With this data, we can confirm that data previously obtained from noninvasive methods with poorer resolution both spatially and temporally may have
electrophysiological correlates within relevant epochs during the experimental
tasks (Driesen et al., 2013).

It is important to acknowledge that an increase in reaction time after
ketamine administration is not always associated with a decrease in
performance. Other visual tasks such as the visual search task exhibited different
results. In this task, monkeys were trained to search in their visual field for a
target stimulus amongst distractor stimuli that were present at a lower luminance.
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Here, it was found that although ketamine was associated with an increase in
SRT towards the target stimuli, this increase in reaction time led to a decrease in
the error rate, presumably due to a longer window within which to select their
target (Shen et al., 2010).

Our results are congruent with these results, as the difference in task
requirements challenges a different set of cognitive processes in the PFC. In the
visual search task used by Shen et al. (2010), the monkey must recognize a
brighter luminance stimulus in a field of dimmer stimuli, termed perceptual
discrimination. In our task, the monkey was able to identify the target stimulus but
difficulties arose in selecting a behavioural response to this stimulus. Rather,
these results for the visual search task further support the ketamine model of
schizophrenia. Studies have found that patients with schizophrenia are less able
to integrate separate elements into a global Gestalt (Place and Gilmore, 1980;
Rief, 1991). Thus, when a number of individual distracting or background stimuli
are presented in their visual field, patients with schizophrenia are better at
processing the items individually. This is in contrast to a control subject’s visual
system, which attempts to integrate the noise together as a single item then
break it down into parts for the search task (Butler et al., 2008).

5.1.2 Ketamine increases background activity to the detriment of task specific
signals
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By far the strongest novel finding of this project is ketamine’s ability to
induce a shift in the signal:noise ratio of task selective activity in the PFC. The
effect was observed in both the spiking activity of individual neurons as well as in
the LFP amplitude of two distinct frequency bands. In the spiking activity we
found that two distinct types of neuron selectivity emerged. Activity in the prestimulus epoch showed rule-based selectivity for the type of trial being performed
(pro- or anti-saccade). Post-saccadic response activity showed that there were
neurons with selectivity for either correct or error trial outcomes, firing more for
their preferred outcome during a specific epoch. Similarly, in the LFP results,
beta band activity showed a significant increase in amplitude moreso after correct
trial outcomes than errors and only during the post-response epoch. There was
also a non-significant trend visualized in the gamma band data during the postresponse epoch. In contrast to the beta band results, gamma band amplitudes
showed a non-significant increase for error trials over correct trials.

The selectivity properties of neurons and LFP amplitudes were recorded
before ketamine administration and their disruption coincides with the onset of
the behavioural symptoms. Most importantly, across both recording modalities
and both trial epochs the cortical function was always disrupted in the same
manner by ketamine; a decrease in the selectivity exhibited by neurons or
frequency bands and an increase in irrelevant non-specific activity.
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For the single cell recordings, this was demonstrated as an increase in the
net firing rate of most neurons to the detriment of the selective signal that they
are responsible for generating. A net increase in neuronal firing rates after
ketamine administration has previously been described (Rowland, 2005), but the
implications of this change have not. The neurons no longer fired more for their
preferred condition and instead fired at an increased rate equally for all
conditions. Further, since the non-epoch baseline firing rate was also increased,
the critical time-locked burst of activity is proportionally smaller in comparison to
the basal rate. The end result of this can be generalized across different neuron
types as a failure to output the selective signals required of them for the expected
PFC functions.

The LFP data can be thought of as a measurement of neuronal coherence
at a single point. When more neurons are firing in an oscillatory pattern, the
amplitude for that oscillatory frequency will be increased at that electrode
recording location. After ketamine administration the post-response beta band
amplitude was decreased to a greater degree after correct trials than error trials,
which had the end result of creating identical post-response activity in an epoch
previously capable of describing the trial outcome. This decreased beta band
amplitude signifies fewer neurons synchronizing their firing rates to the beta band
frequency range and most likely an impaired ability for the brain to generate
signals normally associated with re-enforcement of correct trial behaviour and the
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inhibition of error trial behavior. These results are similar to the ERN changes
described in schizophrenia patients (Kopp and Rist, 1999). In these situations the
EEG signal that normally differentiates between correct and error trials instead
has a similar response for both outcomes.

It is possible that the prefrontal cortex in this ketamine model of
schizophrenia may still be sending the same signals through the appropriate
networks but ketamine increases the global baseline activity of neurons in the
brain which impairs sensitive time-locked bursts of activity. Without this selectivity
in PFC neurons, the ability to code contingent behavioural responses is greatly
reduced and thus the normal flow of information becomes lost in the background
noise. This inefficient activity of the PFC has already been demonstrated in
human patients with schizophrenia. During tasks that challenge the subjects
working memory, fMRI studies have shown that schizophrenia subjects require a
stronger activation (as measured by the BOLD signal) of their PFC in order to
obtain equal or poorer performance rates compared to healthy controls (Callicott
et al., 2003). This excessive workload to only reach levels of normal functioning
may be representing the extra effort exerted in order to create a strong enough
signal to overwhelm the increased background noise. Ramping up neuronal
activity like this would cause significant changes in the BOLD signal of this
region. Even in unaffected healthy subjects, gamma band activity increases
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proportionally in the PFC with the level of cognitive control that the subject
requires to complete a task similar to the anti-saccade task (Cho et al., 2006).

Paradoxically, schizophrenia is usually associated with a hypofrontality
profile and more often demonstrates a decrease in the overall activity in the PFC.
Corroborating this is a recent study that suggests ketamine induces a hypofrontal
state on selective neurons by preferentially inhibiting a select population of
neurons in the primate PFC, which are responsible for advanced cognitive
functions (Wang et al., 2013a). Unfortunately, this study used uncomparable
levels of ketamine which induced a 30 minute dysfunctional state in the nonhuman primates, where excessive levels of nystagmus prevented trial
performance. It is possible that at these higher levels of drug administration,
ketamine overwhelms the brain and no longer selectively binds to the NMDA
receptors of clinically significant Pv+ interneurons (Beasley and Reynolds, 1997).
Newer human studies have also started to find that patients with schizophrenia
exhibit heightened levels of baseline gamma band activity, potentially referring to
the increased activity and increased noise of the PFC after ketamine. This
heightened baseline necessarily then causes all task and epoch analyzed activity
to appear lower after within subject normalization (Kikuchi et al., 2011; Spencer,
2011; Suazo et al., 2014). Antipsychotic medications may be suppressing these
levels as well, which has previously led researchers to classify these regions as
hypoactive (Jones et al., 2012).
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Potential therapeutic interventions incorporating these glutamateric
discoveries are already being investigated. We have previously discussed the
sensitivity of PFC neurons to increases in noise and how this poor information
conductance negatively affects behaviour. As such, simplistic drugs that only act
as agonists or antagonists may not rectify the problem. The poor signal inside the
noise needs to be enhanced and if the glutamatergic signaling system is
disrupted through the NMDA receptor, a potential workaround is through the
metabotropic glutamatergic receptor (mGluR). Agonists for the mGluR receptor
such as LY379268 are showing promising results in clinical trials. By increasing
the glutamatergic signal amplitude (but not the frequency of excitatory postsynaptic potentials), LY379268 facilitates the conveyance of existing signals,
particularly within the PFC (Wang et al., 2013b). A phase 2 clinical trial has
demonstrated that a similar mGluR agonist is as effective as current atypical
antipsychotic medications but is not associated with the metabolic side-effects
that normally accompany these pharmacological interventions (Patil et al., 2007).

5.1.3 Ketamine has opposing effects on beta band and high gamma band LFP
activity in PFC
In the fourth chapter, I demonstrated that beta band LFP activity is
sensitive during the post-response epoch to the monkeys performance in that
trial. Correct outcomes elicited a higher amplitude beta band response than
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incorrect outcomes and ketamine both decreased the overall beta band activity
while also eliminating the outcome selective response. This has an interesting
implication when observed in light of changes documented in the brains of
patients with Parkinson’s disease. This degenerative neurological disorder is
characterized by a progressive inability to generate voluntary movements in the
later stages of the disease. These changes are associated with an increase in
neuronal oscillations in the beta band frequency, as measured by EEG (Chen et
al., 2007). In healthy individuals the beta band oscillations help the brain to favor
an existing motor state and prevent new unwanted movements (Gilbertson et al.,
2005). Voluntary movements can even be slowed by artificially inducing beta
band activity through transcranial current inductions (Pogosyan et al., 2009).
Newer treatment methods of deep brain stimulation (DBS) aim to disrupt these
increased oscillations by delivering asynchronous electrical pulses. Clinical trials
with DBS-based beta band disruption has shown immense promise as once the
pathological beta band activity has been disrupted patients saw a decrease in
their akinesia symptoms (Kuhn et al., 2008).

If the increased beta band activity is associated with a pathological level of
movement or behavioual suppression in the Parkinsonian brain, then the
decreased beta band activity in this ketamine model of schizophrenia may be
representative of the decreased level of cognitive control exhibited by patients
with schizophrenia (Green, 1996). Indeed, patients with schizophrenia show
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decreased beta band synchrony during cognition challenging tasks (Uhlhaas et
al.,

2006).

This

has

been

implicated

in

the

decreased

interregional

communication found in patients with schizophrenia (Uhlhaas and Singer, 2010),
resulting in a disconnected brain and poor PFC interactions with other regions
(Tu et al., 2010).

Compounding these changes are the non-specific changes that we
observed in the high gamma range of LFP amplitude. Gamma band activity has
been associated with the initiation of behavioural responses that require motor
movement. Human EEG studies demonstrated peaks in gamma band activity just
before movement initiation (Shibata et al., 1999). In the diseased state, tests of
working memory have shown increased gamma band activation in patients with
schizophrenia despite poorer performance on the task (Barr et al., 2010) and the
normalization of this heightened gamma band activity recovers performance back
to normal levels (Farzan et al., 2012). Therefore it is possible that the increase in
gamma band amplitude is predisposing the brain to the erroneous initiation of
behavioural responses. With a higher baseline resting state in the gamma band,
the neuronal activation required to reach a threshold for movement initiation can
be reached much more easily. The correlation of this in humans would be an
increased impulsivity, something that has been demonstrated to be increased in
schizophrenia with significant neuronal correlates (Kaladjian et al., 2011). With
both the decreased beta band unable to maintain the current motor set and the
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increased gamma band predisposing the subject to impulsive, poorly planned
behavioural responses, the LFP data provides insight from two different
directions on how aberrant neuronal oscillations and their relation to the
disconnected schizophrenic brain can predispose a patient to have poor cognitive
control over their actions.

5.2 – Caveats and Limitations
5.2.1 Systemic administration of ketamine
One of the problematic areas of working on this project was ketamine’s
action occurring simultaneously on the entire brain instead of only on our region
of interest, the PFC. Debate is still ongoing regarding ketamine’s mechanism of
action for the hyperactivity it induces despite antagonizing a receptor for an
excitatory neurotransmitter (Moghaddam et al., 1997). Since the PFC acts as a
hub with reciprocal connections to many other brain regions, the downstream
effects of the NMDA antagonism in other brain regions may be what is measured
in our studies in the PFC. Yet the infusion of NMDA antagonists into the frontal
cortex of rats has still produced similar behavioural deficits (Murphy et al., 2005).
For its relevance as a model of schizophrenia, ketamine needs to affect the entire
brain to better model the global changes observed in these patients. Although the
effects of ketamine may also be occurring in other brain regions, the PFC acts as
the critical juncture through which the changes in neuronal activity are
manifesting as decreases in cognitive control.
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5.2.2 Single sensory modality
All of our studies made use of the anti-saccade task, which only requires
visual sensory input and behavioural responses in the form of eye movements.
This task was chosen because the neuronal circuitry of these responses is well
understood and has been described in great detail over the years (Everling and
Fischer, 1998). Although patients with schizophrenia exhibit a great many
number of measurable changes in multimodal sensory perception and
behavioural responses, the anti-saccade task has shown replicable results with a
clear impairment in patients (Sereno and Holzman, 1995; Hutton and Ettinger,
2006). Aside from visual behaviour abnormalities, others often employ tasks that
use auditory cues and stimuli to test and schizophrenia-specific EEG findings
have been described in relation to these auditory changes (Blackwood et al.,
1991). For the purposes of this study however, our laboratory is well equipped for
the visual-centric tasks and the training paradigm for the monkeys has been
refined to produce competently performing animals in a minimal amount of time.

5.3 Future directions
5.3.1 Effect of antipsychotic drugs on PFC activity and anti-saccade performance
in the ketamine model of schizophrenia
While we have described strong findings that link the ketamine model of
schizophrenia and potential sources of cognitive dysfunction, a stronger
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connection could be made if the findings observed with antipsychotic medications
in human patients with schizophrenia are also found in this ketamine model.
Traditional typical and atypical antipsychotic medications are unable to produce
changes in the schizophrenic person’s cognitive domain of symptoms, but the
newer mGluR agonists are showing some promise in cognitive benefits
(Moghaddam, 2004; Conn et al., 2009). A study that looked at how these classes
of drugs affect both the single unit recording changes and the LFP changes that
we observed would be very interesting. Being able to strengthen the signal or
decrease the noise would hopefully restore the information that is being lost in
the chaotic activity of the ketamine-treated (and possibly schizophrenic) brain.
Additional non-invasive interventions such as transcranial direct current
stimulation that either enhances the lost beta band activity or decreases the
excessive gamma band activity may also have behavioural implications.

5.3.2 – Changes in LFP-LFP and LFP-spike coherence following ketamine
administration
The work I presented here discussed changes in the LFP amplitude as
recorded from single electrodes. This represents the coherence of neurons at a
specific point but by simultaneously recording from multiple electrodes we can
take these results further. The coherence of LFP activity across multiple sites
both intra and interregional have strong implications when discussing a potential
model of schizophrenia. I have previously mentioned the hypothesis that
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schizophrenia is a disease of disconnect, where through poor anatomical
connections and poor communications between regions the brain becomes
progressively impaired because of an inability to synchronize. We could verify
these hypotheses better by looking at how the brain communicates through
neural oscillations that synchronize activity, the frequency ranges this occurs at,
and how these coherent oscillations are disrupted by ketamine. An additional
dimension could be added by examining how the single unit spiking activity
correlates with the LFP activity. It is possible that the NMDA receptor-inhibiting
actions of ketamine disengage neurons from following the neural oscillations that
normally encourage or discourage spiking activity, thus leading to the noisy and
irrelevant activity pattern.

5.4 Concluding Remarks
Through chapters two through four I have described in detail the
behavioural effects of a subanesthetic dose of ketamine on non-human primates
ability to perform the anti-saccade task. The changes I observed align with
shortcomings in the performance of human patients with schizophrenia who are
tested on this task. These changes were accompanied by decreased taskspecific signals in single unit activity as well as LFP amplitude that also follow
neuronal abnormalities observed in human patients with schizophrenia.
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While schizophrenia is a uniquely human disease, progress with the
ketamine model of schizophrenia will hopefully aid us in determine the true
physiological basis of this debilitating disease. It is my hope that with enough
understanding of the neuronal basis of this disease, optimal interventions can be
made and these patients can enjoy a life enriched by normal cognitive function.
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